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The Influence of Amyloid-Beta, a Major Pathological Marker in Alzheimer's 
Disease, on Molecular Cognitive Processes of APP+PS1 Transgenic Mice 
 
Chad Anthony Dickey 
 
ABSTRACT 
 
 
Alzheimer’s disease (AD) is characterized by anterograde amnesia 
followed by a progressive decline in cognitive function. Post mortem examination 
of forebrain tissue from sufferers reveals the presence of extra-cellular amyloid-
beta plaques, intracellular neurofibrillary tangles, activation of glial cells and 
massive neuron loss. Transgenic mice expressing mutated forms of the amyloid 
precursor protein (APP) and presenilin-1 (PS1) genes develop neuritic amyloid 
plaques, glial cell activation and memory deficits, without the formation of 
intracellular tangles and neurodegeneration.  
The mechanisms by which these transgenic mice develop mnemonic 
deficiencies are unclear. Gene expression of aged memory-deficient APP+PS1 
mice compared with non-transgenic littermates measured by microarray and 
subsequent quantitative real-time PCR (qRT-PCR) analysis revealed 6 inducible 
immediate-early genes (IEGs) and 5 other more stably expressed plasticity-
related genes (PRGs) that were significantly down-regulated in amyloid-
containing hippocampus, but not down-regulated in amyloid-free cerebellum. 
Other genes linked to memory remained stably expressed in both regions. 
Analysis of forebrain AD tissue revealed that all genes measured were down-
 vi
regulated presumably due to neurodegeneration, while the amyloid-free region 
maintained stable expression. IEG expression in APP+PS1 mice was sensitive to 
lower levels of amyloid. However, only in the presence of a substantially larger 
amyloid burden, when memory deficits reliably persist, were both PRGs and 
IEGs down-regulated. Importantly, we found that IEG expression was decreased 
in APP+PS1 mice following exposure to a novel environment, indicating that the 
induction of these IEGs was impaired, rather than the basal expression of resting 
mice.  
Na+/K+ ATPase, an enzyme critical for the maintenance of membrane potential, 
was identified as a down-regulated PRG. We found that activity of this enzyme 
was both impaired in the hippocampi of APP+PS1 mice and specifically inhibited 
by high concentrations of amyloid-beta. Na+/K+ ATPase immunostaining 
revealed decreased protein in the area surrounding the amyloid plaque, where 
dystrophic neurites were visible, indicating amyloid may disrupt ionic gradients 
resulting in neuritic dystrophia. These findings suggest that amyloid accumulation 
may result in the impairment of IEG induction and disruption of the Na+/K+ 
ATPase, possibly eliciting the memory loss developed in APP+PS1 mice.    
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INTRODUCTION 
 
 
ALZHEIMER’S DISEASE.  
 
Memory loss is the primary and most deleterious symptom of AD. 
Sufferers initially lose their cognitive abilities followed slowly by autonomic 
deterioration. AD pathology is characterized by both the extra-cellular cerebral 
accumulation of Aβ 1-42 (Hardy, 1997) and the aggregation of intracellular 
tangles of a hyperphosphorylated form of the tubulin-associated protein, tau (τ) 
(Mattson, 1997). The AD brain is not only characterized by these plaques and 
tangles, but also by neuronal and synaptic loss, as evidenced by the down-
regulation of cytoskeletal- and exocytotic-associated proteins. The severity of AD 
can then be determined based on this collective pathology (Masliah et al., 
2001;Mukaetova-Ladinska et al., 2000;Benowitz and Routtenberg, 1997;Yao and 
Coleman, 1998;Callahan et al., 2002).  
Amyloid precursor protein (APP) is processed post-translationally by 
several proteases known as α-, ß- and γ-secretase. Agonists for the α secretase 
and inhibitors of both the ß- and γ-secretases have shown promise for use in AD 
therapy. The α-secretase cleaves membrane-bound APP within the Aß 1-42 
amino acid site, yielding peptide products that lack any aggregative properties.  
ß-secretase (BACE1) acts closer to the N-terminal of APP leaving a longer 
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fragment for γ-secretase to cleave which results in production of the deleterious 
amyloidogenic Aß 1-42 molecule. The activity of the γ-secretase on the remaining 
membrane-bound portion of APP following ß-secretase cleavage can yield either 
the 1-42 Aβ fragment with fibrillogenic properties or a much less sticky 1-40 
peptide product (Selkoe, 2001;Dewachter and Van Leuven, 2002).  
Whether the 1-40 or 1-42 peptide is produced can be largely dependent 
upon polymorphisms in the presenilin-1 and -2 (PS1 & PS2, respectively) genes 
which greatly influence the activity of the γ-secretase. In fact, mutations in both 
the APP and presenilin genes (denoted as mAPP and mPS1 or mPS2 in 
transgenic models) can influence amyloid plaque formation causing dramatic 
effects on the proclivity of individuals to develop an early-onset form of AD. APP 
mutations can lead to increased amyloid pathology by favoring cleavage of the 
APP N-terminal fragment by ß- or γ-secretase rather than the α-secretase (Citron 
et al., 1997) or by increasing the aggregative properties of the 1-42 peptide itself 
(Wisniewski et al., 1991). Mutations in PS1 or PS2 leading to modified γ-
secretase activity can result in more rapid production of Aß 1-42 (Selkoe, 2001).  
In addition to the neurodegenerative effects of amyloid accretion, other 
adverse consequences of the cerebral deposition of Aβ peptide include 
dysregulation of Ca2+ signaling, mitochondrial damage, free radical production 
(Mattson, 1997;Mattson, 2002) and recruitment of both pro-inflammatory 
components and glial cells (Roses, 2000). Accumulating evidence suggests that 
Aβ precipitates the cascade of pathogenic events leading to the massive 
neurological dysfunction and dementia characteristic of AD (for review see Hardy 
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and Selkoe, 2002). One example of this evidence is that Aβ, through interaction 
with α7 nicotinic receptors (Dineley et al., 2001), initiates the mitogen activated 
protein kinase (MAPK) cascade leading to its over-activation and eventual 
dysregulation. Downstream targets of the MAPK cascade include tau (Arendt, 
2001) and several immediate early genes important for long-term potentiation 
and memory formation. As more evidence becomes available, a clearer 
understanding of the relationship between the various pathological features of 
AD and the best strategy for its prevention will become more apparent. 
Aside from the involvement of the APP and presenilin genes in AD 
progression, the normal role that these genes play in brain function has only 
been clearly defined for presenilin. PS1 proteins are associated with the synaptic 
membrane and weave across it like stitches through fabric. This protein is then 
activated by proteolysis into two subunits which leads to its ability to cleave other 
membrane-associated proteins, including APP and notch (neurite outgrowth-
promoting cell surface glycoprotein), a cell adhesion molecule involved in 
neuronal development and the fate determination of other stem cell types 
throughout life (Milner and Bigas, 1999;Artavanis-Tsakonas et al., 1995). The 
only progress made so far towards identifying the function of APP has been that 
it is a ubiquitous membrane-bound phosphoprotein. Several hypotheses have 
been presented for its role, but none of these have been generally accepted (da 
Cruz e Silva EF and da Cruz e Silva OA, 2003).  
Another gene that is critically linked to the onset of AD is ApoE, a protein 
that is produced by astrocytes and escorts low-density lipoprotein (LDL) through 
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aqueous environments, making it an essential component of the cholesterol 
transport system. There are three alleles of this gene (ε2, ε3, and ε4), which is 
located on chromosome 19, and it has been demonstrated that ApoE ε4 is the 
strongest predictor of late-onset AD (after 60 years of age). Epidemiologic 
studies have revealed that individuals who express the ε4 allele have a greater 
occurrence of late-onset AD compared to those of the more common ε3 allele, 
while those carrying the ε2 allele are protected from AD (Wahrle and Holtzman, 
2003).  Many putative explanations for the action of ApoE on the neuropathology 
of AD exist (for review see Laws et al., 2003). For example, there is evidence 
that ε4 out-competes Aβ for the brain’s protective clearance machinery, allowing 
more plaque-forming peptide to aggregate (St George-Hyslop, 2000). In addition, 
it has been demonstrated that ApoE ε4 has poor membrane repair properties 
(Yang et al., 1997), perhaps indicative of why hippocampal atrophy in AD 
patients with the ApoE ε4 allele is more severe (Lehtovirta et al., 1995).  
The development of transgenic and knockout mice has proven critical to 
the understanding of AD and recent developments have lead to the identification 
of several interesting therapeutic targets, including BACE1 (Ohno et al., 2004) 
and the γ secretase (Eriksen et al., 2003). However, to identify these targets, 
mice with pathological similarities to that of AD patients had to be generated. 
Mice transgenic for the mutant forms of the human APP (Hsiao et al., 1996) and 
PS1 (Duff et al., 1996) genes were generated and our group developed a viable 
doubly transgenic mouse model that expresses both. These APP+PS1 mice 
exhibit accelerated amyloid pathology, microglial activation, astrocyte 
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proliferation, neuritic dystrophia and an impaired cognitive phenotype (Holcomb 
et al., 1998;Gordon et al., 2002).Over the past four years, we have demonstrated 
that these mice develop the hippocampal and cortical Aβ plaques similar to those 
found in the AD brain, and despite the lack of the intracellular fibrillary tangles  
and neuronal degeneration, they do exhibit memory deficits, thereby providing a 
good model for the study of amyloid-associated memory loss (Gordon et al., 
2001;Holcomb et al., 1999;Morgan et al., 2000;Dickey et al., 2001;Jantzen et al., 
2002).  
 
SYNAPTIC PLASTICITY & LTP. 
 The memory deficits exhibited by the APP+PS1 mice provide a potential 
utility in uncovering mechanisms of memory dysfunction. Following the 
application of a tetanic burst of stimulation in the hippocampus, synaptic efficacy 
is greatly increased for as long as several weeks, a phenomenon called long-
term potentiation (LTP). LTP demonstrates that synaptic connectivity of 
hippocampal neurons of the perforant, mossy fiber and Schaffer collateral 
pathways in the cornu ammonis layers 1 and 3 (CA1 and CA3) can be modified 
structurally and electrically following a burst of high frequency stimulation 
(Winder and Schramm, 2001;Zola-Morgan et al., 1986;Tsien et al., 1996;Malenka 
and Nicoll, 1999;Shapiro, 2001). This event results in the activation of N-methyl-
D-aspartate receptors (NMDAR), allowing the second messenger ion, Ca2+, into 
the cell. This is an associative process requiring depolarization of the synaptic 
membrane via activation of aminomethyl-phosphonic acid   receptors (AMPAR) 
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which dislodges the Mg2+ ion blocking the NMDAR pore and the binding of extra-
cellular glutamate to open the ligand-gated NMDAR calcium channel.  
Modification of the pre-synaptic cell is also required for LTP and this process 
seems to be induced by a retrograde messenger released from the post-synaptic 
neuron, such as nitric oxide (NO; Kandel et al., 2000).  
The LTP phenomenon is thought to result from changes in the morphology 
and receptor properties of synapses that are dependent on Ca2+ activated 
mechanisms in the cell. One mechanism of the modulatory nature of Ca2+ may 
be attributed to the activation of Ca2+/calmodulin kinase II α (CaMKIIα, the 
catalytic subunit of CaMKII), as demonstrated both by the inability of neurons to 
induce LTP when CaMKIIα is specifically inhibited (Perkel et al., 1990) and the 
failure of targeted CaMKII knockouts to elicit LTP (Silva et al., 1992). This 
enzyme seems essential for the initiation (Otmakhov et al., 1997) of LTP, which 
can persist from hours to weeks. The discrepancy in the duration of LTP is not 
understood, although the transition from induction to maintenance seems critical. 
One hypothesis for the ability of LTP to be maintained is that of the silent 
synapse which proposes that post-synaptically silent neuronal junctions can 
become activated either by recruitment of new AMPARs to the membrane or by 
the spillover of glutamate onto nearby NMDAR synapses (Winder and Schramm, 
2001). Currently there are two accepted phases of LTP, aptly named the early 
(within the first 30 minutes of stimulation) and late (beginning 30 minutes after 
stimulation) LTP phases. What distinguishes the two from each other is the 
requirement of de novo protein synthesis in the late phase (Bolshakov et al., 
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1997;Ma et al., 1999). A proposed synthesis-independent intermediate phase 
has also been described that requires the activation of protein kinase A (PKA) 
and its modulation of several key signal transduction cascades (Nayak et al., 
1998). Early phase LTP, which has been functionally linked to short-term 
memory, requires only NMDAR and protein kinase C (PKC) activation (Huang et 
al., 1996), two effects well upstream of gene transcription.  When an intense late 
phase stimulating current such as maximal electro-convulsive seizure (MECS, 
stimulates neurons in a similar way as LTP, but more reproducibly) is 
administered, rapid induction of a group of genes known as immediate early 
genes (IEGs, so named because they do not require new protein synthesis for 
transcription) ensues (Cole et al., 1990;Lyford et al., 1995). The regulated 
expression of these genes provides modulatory effects on neuronal structure and 
function through manipulation of a network of constitutively expressed proteins, 
implicating them in enduring forms of LTP, and therefore long-term memory 
formation. 
 An initial shortcoming of LTP was that it required a very intense induction 
stimulus (several short successive applications of ~100Hz) well outside of the 
physiological range (Tsukada et al., 1994). However, in 1999, Winder et al. 
demonstrated that oscillations emitted by hippocampal neurons during 
exploratory behavior called the theta (θ) frequency (3-13Hz) can induce LTP, but 
activation of the ERK/MAPK cascade is required (Winder and Schramm, 
2001;Bach et al., 1995). Another mechanism that induces synaptic plasticity is 
the application of low frequency stimulation (1Hz) for a prolonged period, causing 
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long-term depression (LTD; Dudek and Bear, 1992), which results in lowered 
excitability of the cell for prolonged periods. Therefore, there are two 
mechanisms that can induce synaptic plasticity within the hippocampus, LTP and 
LTD, both with opposite effects. Interestingly, a phenomenon known as synaptic 
history has been described in which differential phosphorylation of AMPARs 
results in different enzymatic specificity, with LTP being correlated with CaMKII 
specificity and LTD with PKA specificity (Mayford et al., 1995;Lee et al., 2000). 
Still, other forms of NMDAR-independent LTP are found at the CA3 mossy fiber 
pathway and also in the cerebellum at the Purkinje-parallel fiber synapse (Winder 
et al., 1999). These mechanisms may involve the mitogen activated protein 
kinase (MAPK) cascade and other unknown components. In summary, the 
activation of post-synaptic neurons can elicit signal transducing mechanisms 
(Ca2+, MAPK, etc) that eventually lead to changes in synaptic efficacy through 
altered gene expression. 
 
BEHAVIOR.  
  Recent evidence reveals that several activity-inducible IEGs, along with 
other constitutively expressed proteins, are up-regulated in animals exposed to 
novel environmental stimuli and tasks that require learning, further supporting the 
notion of gene induction mediating memory storage. Different aspects of learning 
and memory, such as spatial navigation, location learning, consolidation, and 
retrieval, seem to require different expressional patterns of these genes. Animal 
models generated with selective expression or disruption of some of the 
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constitutively expressed LTP-associated genes have had varying success at 
linking LTP to specific types of memory (Tsien et al., 1996;Tang et al., 1999;Silva 
et al., 1992;Mansuy et al., 1998;Huang et al., 1996).  
The ability to determine defects or improvements in various forms of 
memory in these transgenics requires the employment of several well-accepted 
training batteries. The Morris water maze is most often used to assess memory 
retention. It places a mouse in a pool of opaque water with a small flagged 
platform just beneath the surface (Morris, 1984). The mouse’s aversion to 
swimming provides the impetus to search for the platform, and once it is found, a 
normal mouse should be able to locate it quickly in subsequent trials by 
recognizing the flag as a cue. A hippocampal-dependent version of the trial 
incorporates the use of visual cues outside of the pool, making this a spatial 
navigation task. Another spatial test that removes water as the aversion and 
replaces it with an obtrusive noise and bright light is the Barnes maze (Barnes, 
1979). Here, animals are placed in an open field with holes surrounding the 
perimeter, one of which exits to an escape tunnel. Cognitive abilities are 
measured in a similar manner as that of the Morris water maze, either by cuing 
the animal with a flag near the escape tunnel opening and measuring errors 
made in trials following learning of the flag location or by placing exterior visual 
cues around the field without the flag for hippocampal-dependent learning 
assessment.  
Contextual fear conditioning is another means of measuring memory that 
uses an aversive stimulus (normally electric shock) coupled to a sound. The 
 10
animal eventually learns to “freeze” in response to the sound, preventing it from 
receiving an additional shock. Social transmission of food preference (Kogan et 
al., 1997) utilizes a tester mouse that is exposed to a food with a particular scent. 
This animal is then readmitted to the general population and these other mice are 
exposed to food with the same scent used earlier and a new scent. These 
animals exhibit learning if they only eat the food that the tester had eaten 
because they know that it is safe. One other example is novel object recognition 
(Mansuy et al., 1998;Mumby et al., 1996;Myhrer, 1988), in which a mouse is 
exposed to two objects for some time. Then, with the addition of a third object, 
learning is determined by increased latency with this new object. 
Animals such as the GluR1 knockout (KO) mouse (Zamanillo et al., 1999), 
the CaMKIIα KO mouse (Silva et al., 1992), and the calcineurin KO mouse  
(Mansuy et al., 1998) have demonstrated impaired performance in behavioral 
tasks and reduction in LTP phenotype. However, one particular animal over-
expressing the NMDAR subunit NR2B exhibited marked increases in both LTP 
and behavioral task performance, edifying the possibility of memory being 
influenced by NMDAR-dependent LTP (Tang et al., 1999).  
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CONSTITUTIVE PROTEIN EXPRESSION. 
 The properties of several constitutively expressed genes make them 
excellent targets for future memory-related studies. Aside from proteins essential 
for the basic functions of neurons such as the Na+/K+ ATPase, other key 
components of the LTP system of memory formation are neurotransmitter 
receptors. The NMDAR is an ionotropic glutamate receptor that also requires 
glycine binding as a co-agonist for activation, and is composed of several 
heteromeric transmembrane subunits. There are three types of subunits (NR1, 
NR2 and NR3), each with a variable number of isoforms designated by a letter 
(for example, four isoforms of NR2 include NR2A, NR2B, NR2C and NR2D; Cull-
Candy et al., 2001). Each receptor requires the incorporation of several NR1 
subunits and at least one NR2 subunit. NR3 can co-assemble with any NR1/NR2 
complex. The NR2 subunit determines the rate of current decay through the 
channel and the affinity of the receptor for glutamate, while NR1 determines the 
affinity for glycine. NR2A and NR2B elicit a high conductance coupled with a high 
affinity for extra-cellular Mg2+, while NR2C and NR2D exhibit the opposite effects 
(Cull-Candy et al., 2001). Interestingly, during development NR2B and NR2D are 
highly expressed, but as maturation progresses they are replaced with NR2A or 
NR2C resulting in a faster rate of current decay. This illustrates a possible 
explanation as to how constitutive over-expression of NR2B may result in 
memory enhancement (Tang et al., 1999).  
As previously noted, AMPARs are also fundamental to the induction of 
LTP, providing enough depolarization upon ligand-binding to release the Mg2+ ion 
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that blocks the NMDAR channels. These receptors have several isoforms, each 
with varying affinities for glutamate and conductance properties. AMPARs have 
even been directly linked to NMDARs via modulatory proteins, allowing crosstalk 
between the two channels (Soderling and Derkach, 2000). In AD, AMPARs have 
an altered expression, and this may contribute to the associated dementia. 
Modulation of plasticity and LTP also involves the presence of “sensors” 
on the post-synaptic membrane that can modify synaptic connectivity. One such 
protein is a recently described gene product called calsyntenin-1 (CSTN-1), a 
transmembrane protein that is specific to post-synaptic dendrites (Vogt et al., 
2001). The cytoskeletal domain binds Ca2+ and undergoes a conformational 
change allowing serine proteases in the synaptic cleft to cleave the extra-cellular 
portion. The inner subunit may then serve as a Ca2+-signaling molecule that 
associates with the spine apparatus at the base of the dendritic shaft, a structure 
that has been postulated to be responsible for acquisition of extra membrane 
material during synaptogenesis. Another non-IEG protein that seems to be 
associated with post-synaptic plasticity is synaptopodin, a molecule that 
associates with actin filaments specific to the dendritic tree in the hippocampus, 
cortex, and striatum (Mundel et al., 1997). This protein has protein kinase C 
(PKC) phosphorylation sites along with a C-terminal 90 amino acid repeat 
domain that is common to the PDZ family of proteins (Mundel et al., 1997). Upon 
induction following LTP, synatopodin’s linear motif allows side-to-side 
arrangement with actin, possibly serving as a mediator between the cytoskeleton 
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and other associated proteins, facilitating the subsequent filopodia extension and 
retraction properties that PSDs exhibit. 
 Calmodulin is an intracellular adapter molecule that binds Ca2+ ions 
following synaptic transmission. CaMKII is an extremely important neuron-
specific serine/threonine kinase that auto-phosphorylates upon binding of the 
Ca2+/calmodulin complex. This auto-phosphorylation maintains CaMKII in an 
active state even after Ca2+ levels have dissipated. The α subunit of CaMKII is 
the catalytic domain of the enzyme and the mRNA for this gene is present at 
dendrites, suggesting dendritic translation by the polyribosomes located there 
(Steward and Levy, 1982;Steward, 1987). Transgenic mice expressing a 
constitutively phosphorylated, and therefore active form of CaMKII are incapable 
of expressing θ frequency induced LTP, in fact LTP is converted to LTD in these 
animals (Bach et al., 1995;Mayford et al., 1995), rendering them unable to 
perform spatial memory dependent tasks. However, these mice are able to learn 
from a contextual conditioning trial, lending further credence to the notion of the 
significant role intermediate frequencies play in fine-tuning cognitive functions. 
Therefore, CaMKII is essential to the induction and maintenance of LTP, 
probably attributed to its specificity for countless substrates.  
Among these substrates are components of the vesicular exocytosis 
system involved in neurotransmitter release (Turner et al., 1999). Briefly, 
synapsin 1 attaches vesicles to actin filaments of the axonal cytoskeleton until 
phosphorylated. Once released, two proteins on the plasma membrane, syntaxin 
and SNAP-25, bind synaptobrevin on the vesicular membrane. The Ca2+ sensor, 
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synaptotagmin, is also located on the vesicle and allows release only if Ca2+ is 
bound (Brunger, 2000). Not only are all of these pre-synaptic proteins a substrate 
for CaMKII, reiterating its powerful capability to modulate all aspects of 
neurotransmitter release and therefore LTP induction, but many post-synaptic 
substrates exist as well, such as AMPARs and other receptors, explaining it’s 
presence at the PSDs, and demonstrating it’s role in LTP maintenance.  
 
IEG EXPRESSION. 
In 1990, Cole et al. created a phage library from MECS stimulated 
hippocampal cells, which subsequently lead to the identification of several genes 
that seemed to be maximally expressed in response to this LTP-like stimulation 
(Cole et al., 1989). Previously, it was demonstrated that ubiquitous transcription 
factors such as c-fos (Morgan et al., 1987) and zif268 (Cole et al., 1989) are 
induced within a short time of seizure activity and a progressively stronger 
stimulus increases the abundance of these IEGs’ mRNAs. The library created by 
Cole et al. revealed 15 activity-inducible IEGs, half being transcription factors, the 
other half being previously undescribed protein effector genes able to influence 
processes such as cell and neurite growth, signal transduction and cytoskeletal 
rearrangement (Lanahan and Worley, 1998). 
The transcription factors from this group of 15 include mostly ubiquitous 
transactivators, such as c-fos, c-jun (which together form AP-1), Nur77 (NGFI-B), 
Egr3 and Zif268 (Egr1/NGFI-A), both of the latter being zinc-finger transcriptional 
regulators. Both Nur77 and Zif268 are of interest because their mRNA can be 
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induced rapidly by nerve growth factor (NGF).  Zif268 is of particular interest 
because it’s mRNA is rapidly upregulated both in the hippocampus of rats after 
exposure to a novel stimulus (Hall et al., 2000) and in the temporal gyrus of 
monkeys following associative learning tasks (Miyashita et al., 1998). 
Additionally, viable heterozygous Zif268 knockout mice exhibit both long-term 
memory deficits and more rapid decay of LTP than wildtype littermates (Jones et 
al., 2001).  
The Zif268 promoter contains 2 cAMP responsive elements and therefore 
it is assumed that Zif268 transcription is modulated by CREB (Changelian et al., 
1989;Sakamoto et al., 1991). In addition, the MAPK cascade appears to regulate 
Zif268 transcription following LTP induction (Davis et al., 2000). Zif268 
expression is also tempered by the negative regulator NAB-2, a Zif268-specific 
transcriptional repressor protein that is very similar to Stat6 (Abdulkadir et al., 
2001). Therefore, there is both a constitutive (CREB) and inducible (MAPK 
cascade) mechanism controlling Zif268 expression, neither of which require any 
de novo protein expression, while phosphorylation or dephosphorylation of NAB-
2 may well be the “switch” that determines when an increase in Zif268 mRNA is 
necessary. Zif268 binds the consensus GCG(T/G)GGGCG and can induce the 
expression of many cellular factors, including growth factors, cytokines and cell 
adhesion molecules, that are essential for the specificity involved with synaptic 
plasticity (McCaffrey et al., 2000;Khachigian et al., 1996;Kramer et al., 
1994;Maltzman et al., 1996), properties that warrant the tight regulation of Zif268 
expression.  
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Nur77 mRNA, in addition to NGF responsiveness, has also been shown to 
be induced by electroconvulsive seizures (Watson and Milbrandt, 1989), 
amphetamine administration (Werme et al., 2000;St Hilaire et al., 2003) and 
other stress-inducing stimuli (Kovacs and Sawchenko, 1996). It is linked to 
inhibitory processes in the dopaminergic system assisting in molecular 
mechanisms responsible for fine control of motor function (Drolet et al., 2002). 
Nur77 is an orphan thyroid hormone receptor gene that undergoes rapid post-
translational modification and phosphorylation (Fahrner et al., 1990). Additionally, 
it binds to DNA consensus sequences similar to that of thyroid hormone receptor, 
however, unlike other known members of the thyroid hormone receptor 
superfamily, it does not require dimerization in order to bind as a transactivator 
(Wilson et al., 1992). The role of Nur77 in memory consolidation has not been 
well established, and it remains unclear as to whether this gene is linked to the 
learning process or simply the stress elicited by exposure to behavioral 
paradigms.  
The group of effector IEGs elicited by MECS includes several proteins 
with extremely novel characteristics. ß-activin is a transforming growth factor 
implicated in neuronal survival that is predominately involved in developmental 
processes (Andreasson and Worley, 1995). Rheb, a Ras homologue, is a small 
GTP-binding protein that interacts with Raf kinase and seems to integrate growth 
factor signals with PKA-signaling cascades specifically in PSDs where both of 
these components are activated (Yamagata et al., 1994). Therefore, Rheb may 
utilize the hierarchical Ras/Raf cascade to provide highly localized responses to 
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many growth factors, since signaling would be restricted to those molecular 
layers with activated PKA. Another effector IEG with unique properties is a 
member of the pentraxin family called Narp. This protein is thought to be 
secreted into the synaptic cleft and promote clustering of pre- and post-synaptic 
AMPA receptors (O'Brien et al., 2002), therefore altering plasticity and possibly 
establishing the lasting cellular changes necessary for long term memory 
formation.  
Perhaps the two most intriguing members from this group of IEGs are an 
inducible form of a metabotropic glutamate receptor binding protein called Homer 
that is found only in activated synapses and the activity-regulated cytoskeletal 
associated protein (Arc). Three Homer genes encode Homer-1, 2, and 3 proteins 
(Bottai et al., 2002), all modulators of intracellular Ca2+ release. The three Homer 
proteins and their isoforms all have an EVH1 domain specific for a proline rich 
motif present in metabotropic glutamate receptors (mGluR1 and mGluR5), 
ryanodine receptors, IP3 receptors and Shank proteins. This domain links 
mGluRs and NMDARs with intracellular Ca2+ stores. Other Homer functions 
include regulation of 1) spontaneous activity innate to mGluR1, mGluR5 and K+ 
channels, 2) directed axonal outgrowth, and 3) dendritic spine morphology. In 
particular, the Homer-1 gene gives rise to two IEG products following neuronal 
activity, Homer-1a and Ania3, by a novel conversion of an intronic sequence to a 
coding exon (Brakeman et al., 1997).  
The inducible IEG promoter contains a CRE-site, once again implicating 
CREB and the MAPK signaling cascade in LTP-mediated gene induction. These 
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IEG products are much smaller than the constitutive Homer-1 gene isoforms, 
Homer-1b and 1c, which express a bulky oligomerization domain that seems 
critical in preventing their migration across the axon hillock (Bottai et al., 2002). 
LTP requires a precise ratio of mGluRs in both the post- and pre-synapse, and 
crosstalk between pre-synaptic mGluR5 subunits and post-synaptic NMDARs via 
Shank proteins has been demonstrated (Ango et al., 2000). Therefore Homer-1a, 
lacking the restrictive multimerization domain, competes with the constitutive 
isoforms for binding sites on the C-terminus of newly synthesized metabotropic 
glutamate receptors and serves as a “homing” signal for the mGluRs to the pre-
synapse. In fact, the more LTP-inducing stimulus applied to the neuron, the 
larger the induction of Homer-1a protein compared with -1b and -1c, resulting in 
more mGluRs being targeted to the dendrites. Once the receptors are delivered, 
Homer appears to dissociate and be targeted for degradation, attributed to an 
ubiquination domain within the IEG product. The presence of specific mGluR 
subunits at the pre-synaptic membrane may indicate both their functional 
significance as synaptic glutamate sensors and their ability to potentiate 
glutamate release in an extra-cellular concentration-dependent manner. These 
features, coupled with the ability of mGluR5 to crosstalk with post-synaptic 
NMDARs, may demonstrate that LTP is maintained through direct interaction 
between the pre- and post-synaptic neuron, underscoring the importance of the 
inducible IEG Homer-1a in mediating this positive feedback mechanism. 
Arc exhibits the most unique traits of any of the IEGs elucidated from the 
MECS library. Following an LTP inducing stimulus, Arc mRNA is rapidly 
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upregulated in a matter of 15 minutes within the cell body layer of neurons. By 30 
minutes, the mRNA is detected near the dendritic spines. By 1 hour Arc protein is 
detected in distal branches of the dendritic trees, demonstrating that Arc is 
translated locally on the polyribosomes present at the dendrites (Lyford et al., 
1995). These polyribosomes are dormant except at synapses with activated 
mGluRs, therefore local translation at the dendrites is only possible when those 
synapses are active (Weiler and Greenough, 1993;Steward and Worley, 
2001;Steward, 1995), providing selective expression of transcripts such as Arc. 
Other mRNAs that are translated by dendritic ribosomal rosettes are the catalytic 
α domain of CaMKII and microtubule-associated protein 2 (MAP2), both of which 
are derived from constitutively expressed genes (Wallace et al., 1998). This 
leaves Arc as the only identified inducible IEG product that is locally translated at 
activated synapses. 
 Recent studies have provided additional information about Arc that makes 
it an intriguing candidate for memory-related studies. Guzowski et al. injected Arc 
antisense oligonucleotides into the brains of rats and using a spatial water maze 
task demonstrated that long-term memory consolidation was significantly 
impaired, while short-term cognition was not (Guzowski et al., 2000). Also, in 
concordance with the idea that early phase LTP corresponds to short-term 
memory, and late phase LTP (which requires new protein synthesis) with long-
term memory, animals injected with Arc antisense oligos were able to undergo 
induction of LTP, but were unable to maintain it. Arc induction also seems 
dependent upon NMDAR activation, while AMPAR stimulation alone will not 
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produce a rise in expression (Steward and Worley, 2001). Additionally, animals 
exposed to an enriched environment have increased hippocampal levels of Arc 
expression, and animals most proficient at spatial tasks have had correlated 
elevations in Arc mRNA levels (Montag-Sallaz et al., 1999;Pinaud et al., 
2001;Guzowski et al., 2001). The expression of Arc appears to be highest 
following a novel task, as demonstrated by a decrease in expression in mice 
over-trained for the same trial. Likewise, by simply changing the location of the 
platform in the water maze, Arc levels become elevated (Kelly and Deadwyler, 
2002). All of these data correlate well with the notion that some sort of enduring 
synaptic rearrangement is essential for the consolidation of long-term memory. 
Taken together with the properties of the Arc protein and its expression patterns, 
these findings belie the possible mechanistic role of Arc in memory formation. 
  Arc co-sediments with F-actin macroaggregates and bears some 
homology with α-spectrin, further implicating it in mediation of synaptic plasticity. 
The protein is a 45kD hydrophilic protein with several phosphorylation sites 
including sites for PKC and CaMKII. Arc is expressed basally at low levels, with 
the thought being that this protein is induced during any NMDA-mediated 
synaptic activity. This relationship was established by findings of a reduction in 
the basal mRNA levels following NMDAR antagonist, MK-801, administration 
(Lyford et al., 1995), accompanied by a robust increase when animals receive 
methamphetamine (Kodama et al., 1998). The expression of Arc mRNA is almost 
exclusive to the brain, and predominates in the hippocampus and cortex. Cortical 
levels are actually higher than those of the hippocampus, further implicating a 
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functional relationship with long-term memory storage through LTP maintenance 
and lasting synaptic changes in the PSDs of cortical neurons. Following an LTP 
inducing stimulus, the rapid induction of mRNA reaches a maximal level within 1 
hour and this peak is maintained for 8 hours, followed by a return to basal 
expression levels within 24 hours.  
A signal within the mRNA itself seems the mechanism for the selective 
transport of particular mRNAs to the dendrites. This trafficking is a two-step 
process consisting of two types of signals within the molecule; a routing signal, 
for selective nuclear retention or molecular layer transport, and a localization 
signal, that results in the selective accumulation of mRNA at a particular 
intracellular site (Steward et al., 1998). Both Ca2+ and cAMP induce Arc 
transcription, and this inducibility is dependent upon the activation of PKA and 
the ERK/MAPK cascade (Waltereit et al., 2001). Interestingly, the Arc promoter 
lacks a complete putative CRE site, tentatively eliminating CREB transcriptional 
activation, a common downstream target of the MAPK pathway. The promoter 
does however contain an AP-1 binding site, a transcription factor composed of 
the two IEGs, c-fos and c-jun, possibly indicating a potential regulatory 
mechanism that provides activity-dependent modulation of transcriptional 
activation.  
Growth factors have also been implicated in LTP-promoted Arc induction, 
namely insulin (Kremerskothen et al., 2002) and brain-derived neurotrophin 
factor (BDNF;Yin et al., 2002). Insulin seems to mediate Arc expression through 
the ERK/MAPK cascade, and BDNF, known to activate CREB and the MAPK 
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cascade, has also been linked to an increased expression of Arc. Therefore, 
Ca++ influx that activates PKA and subsequently the MAPK cascade, may 
mediate the CREB-independent activation of Arc transcription, emphasizing the 
possibly significant roles that effector IEGs and the ERK/MAPK cascade play in 
cognitive retention. 
 
THE ROLE OF NA+/K+ ATPASE IN COGNITIVE FUNCTION. 
 The role of the membrane-bound Na+/K+ ATPase is to transport Na+ ions 
out of the cytosol and K+ ions in to the cell against their concentration gradient 
thereby establishing a membrane potential to allow subsequent depolarizations. 
This process requires energy input that is derived from ATP hydrolysis. The 
importance of this enzyme in cognitive processes is belied by its consumption of 
~40% of total cerebral ATP. It has been previously established that specific 
inhibition of Na+/K+ ATPase by oubain, prevents the consolidation of memory 
(Mark and Watts, 1971;Watts and Mark, 1971), and therefore it is postulated that 
the ability of neurons to conduct action potentials or facilitate LTP is critically 
dependent on the integrity and functionality of this enzyme.  
In addition to 3 tissue-specific subtypes of the Na+/K+ ATPase, there are two 
major subunits that comprise each molecule; a catalytic α subunit and a 
membrane anchoring β subunit. Very recent evidence indicates the presence of a 
cerebral γ subunit, a member of the FXYD family, which positively regulates the 
activity of Na+/K+ ATPase (Crambert et al., 2003). This subunit is a single 
transmembrane protein, however much of its function has yet to be determined. 
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The activity of Na+/K+ ATPase can be increased or decreased by pharmacologic 
intervention with the anti-convulsant phenytoin or the cardiac glycoside digitalis, 
respectively. Phenytoin decreases the intracellular concentration of Na+ ions by 
two possible mechanisms; inhibition of voltage gated Na+ channels by locking 
them in an inactivated state (Worley and Baraban, 1987;Kuo and Bean, 1994) 
and/or the hyper-activation of Na+/K+ ATPase (Gutman and Boonyaviroj, 1977) 
by preventing the phosphorylation of the α subunit and thereby blocking its 
internalization (Guillaume et al., 1989). 
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ApoE      9   
Homer-1a 9  9 9 9   9 
Calsyntenin-1 9   9    9 
Zif268 9  9 9 9    
Arc 9  9 9 9   9 
Nur77 9  9 9     
Narp 9  9 9 9  9 9 
Na+/K+ ATPase    9 9 9 9 9 
AMPA1   9 9 9   9 
CaMKIIα  9 9 9 9  9 9 
Gap43   9 9  9 9  
GAPDH         
GFAP      9   
NMDA2B   9 9 9   9 
Synapsin-1  9    9 9  
Syanptopodin   9 9  9  9 
Synaptotagmin  9    9 9  
NAB2         
Syntaxin  9    9 9  
Vimentin    9  9 9  
Neurofilament M    9   9  
Synaptophysin  9    9 9  
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ABSTRACT 
A critical question in Alzheimer's disease (AD) research is the cause of memory 
loss that leads to dementia. The APP+PS1 transgenic mouse is a model for 
amyloid deposition, and like AD, the mice develop memory deficits as amyloid 
deposits accumulate. We profiled gene expression in these transgenic mice by 
microarray and quantitative RT-PCR (qRT-PCR). At the age when these animals 
developed cognitive dysfunction, they had reduced mRNA expression of several 
genes essential for LTP and memory formation (Arc, Zif268, NR2B, GluR1, 
Homer-1a, Nur77/TR3). These changes appeared to be related to amyloid 
deposition, as mRNA expression  was unchanged in the regions that did not 
accumulate amyloid.  Transgene expression was similar in both amyloid-
containing and amyloid-free regions of the brain. Interestingly, these changes 
occurred without apparent changes in synaptic structure, as a number of 
presynaptic marker proteins (GAP-43, synapsin, synaptophysin, synaptopodin, 
synaptotagmin, syntaxin), remained stable. Additionally, a number of genes 
related to inflammation were elevated in transgenic mice, primarily in the regions 
containing amyloid. In AD cortical tissue the same memory-associated genes 
were down-regulated. However, all synaptic and neuronal transcripts were 
reduced, implying that the loss of neurons and synapses contributed to these 
changes. We conclude that reduced expression of selected genes associated 
with memory consolidation are linked to memory loss in both circumstances. This 
suggests that the memory loss in APP+PS1 transgenic mice may model the early 
memory dysfunction in AD prior to the degeneration of synapses and neurons. 
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INTRODUCTION 
Memory loss is an early and progressive symptom of Alzheimer’s disease (AD). 
During the period of cognitive decline, pathological hallmarks such as amyloid 
plaques and neurofibrillary tangles become evident (Selkoe and Hardy, 2002).  In 
the later stages of AD, there is a profound loss of synaptic markers, but early in 
the disease this loss is modest, and in some instances not discernable 
(Mukaetova-Ladinska et al., 2000;Tiraboschi et al., 2000;Masliah et al., 
2001;Minger et al., 2001).  A clue to understanding the basis of early memory 
loss in AD may come from transgenic mice that develop impaired memory 
function associated with amyloid deposition, but never show the extensive loss of 
synapses or neurons typical of AD.  
The APP+PS1 mouse model of amyloid deposition develops a memory 
loss that is consistently observed by 15 months of age (Morgan et al., 
2000;Arendash et al., 2001) and is correlated with the extent of amyloid 
deposition.  Like AD, these mice deposit amyloid primarily in the cerebral cortex 
and hippocampus, leaving the brainstem and cerebellum largely unaffected 
(Holcomb et al., 1998;Holcomb et al., 1999;Gordon et al., 2002). To assess 
changes that occur in the brain in conjunction with amyloid- associated memory 
loss we used microarray analysis and qRT-PCR to survey the genes that were 
up- or down-regulated in amyloid-containing regions of APP+PS-1 transgenic 
mouse brain. We found that the amyloid-containing regions of the transgenic 
mouse brain had high levels of expression of inflammation-associated genes, a 
characteristic that is also typical of AD brain. However, the most intriguing part of 
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the gene expression profile was a selective decrease in transgenic mice of genes 
known to be important in long-term potentiation (LTP) and memory consolidation, 
restricted to amyloid-containing brain regions. Expression of genes involved in 
synaptic and neuronal structure was severely diminished in the human AD brain, 
but the transgenic animals did not show decreases in any of these genes.  This 
suggests that the memory deficits in the early stages of human AD may be the 
result of dysfunctional changes that precede the frank loss of synapses.  
 
METHODS 
Materials 
 Mice were bred in our facility and genotyped using previously described 
methods (Gordon et al., 2001).  All mice were 17-18 months of age at time of 
death. Mice were deeply anesthetized with pentobarbital (100 mg/kg) and 
perfused transcardially with phosphate buffered saline. Brains were quickly 
removed and amyloid-containing (cortex and hippocampus) and amyloid-free 
areas (cerebellum, striatum, and brainstem) were immediately dissected and 
frozen on dry ice.  For microarray analysis, cortex and hippocampus were pooled 
and dealt with as amyloid bearing samples, while cerebellum, striatum and 
brainstem were combined and treated as amyloid-free tissues. For qRT-PCR, 
hippocampal RNA alone was isolated and regarded as amyloid-containing while 
cerebellum alone was used for amyloid-free analysis. Transgenic and non-
transgenic animals were sacrificed in random order to minimize unintentional 
bias in handling of the samples. The working memory performance of the 
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APP+PS1 mice used in these studies was significantly different from their non-
transgenic littermates used as controls (Austin et al., 2003). 
 Fresh-frozen human cerebellar and medial temporal gyrus (MTG) 
specimens were obtained from the Brain Donation Program at Sun Health 
Research Institute in Sun City, Arizona.  Subjects with a clinical history of 
dementia were diagnosed as AD using neuropathologic consensus criteria, 
including those published by CERAD (Mirra et al., 1991) and the NIA-Reagan 
Institute (1997). Control subjects did not have a clinical history of dementia and 
did not meet neuropathologic criteria for AD or other neurologic disorders. The 
average postmortem intervals were 2.6 h for AD and 2.3 h for control specimens 
(6 Female, 2 Male for AD; 6 Female, 2 Male for age matched control). The 
average age for the AD specimens was 87 years, and the average age for the 
controls was 88 years. 
 
Microarray analysis 
Brain specimens from four 17-18 mo old APP+PS1 transgenic mice or four 
non-transgenic littermates were grouped into two categories; amyloid-containing 
(cortex and hippocampus) and amyloid-free areas (cerebellum, striatum, and 
brainstem).  Messenger RNA was isolated from individual tissue samples, 
labeled with Cy3 or Cy5, and used for competitive hybridization to cDNA 
microarrays as described (Loring et al., 2001).  Samples were analyzed pair wise 
(matched areas from transgenic and non-transgenic animals) on a total of 16 
microarrays.  The microarrays (8 Rat LifeArray 1 and 8 Rat LifeArray 2; 4 each 
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for the amyloid-containing region samples and the amyloid-free regions) used for 
this study were constructed from a collection of 15,981 rodent cDNAs 
representing 10,060 different genes (Incyte Genomics, Inc). All of the sequences 
differentially expressed in the present study are more than 90% identical in 
mouse and rat and competitive hybridization of rat and mouse brain transcripts to 
these microarrays showed that 89% of the cDNA clones hybridized mouse and 
rat samples equally (data not shown).  Microarrays constructed from the same 
library are currently available commercially from Agilent Technologies (Palo Alto, 
CA).  Data collected from the microarray hybridizations were subjected to two 
low-frequency data correction algorithms to compensate for systematic variations 
in data quality as described previously (Yue et al., 2001).  
 To minimize the detection of false positive signals (Type I statistical 
errors), the data were subjected to a two-stage criterion to identify genes of 
interest. The limit of detection of differential expression (LDDE) was calculated to 
be ±1.4 fold by multiple quality control hybridizations as previously described 
(Yue et al., 2001).  This LDDE indicates that in a single hybridization of an RNA 
sample against itself a 1.4 fold difference occurred with a P < 0.01.  To further 
limit the number of false positive genes identified, we required that in 3 of the 4 
individual hybridizations the differential expression value had to exceed 1.4 for a 
given gene to be analyzed further.  For the second criterion, the statistical 
significance of the average differential expression value for any gene was 
calculated using Z-scores and a NORMSDIST function, and was required to 
exceed a value of 1.4 (not simply 1.0) with a P < 0.05.  In cases where a given 
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gene was represented by multiple sequences on the microarray, all data were 
combined for statistical analysis. Detailed analysis indicates that some 
sequences on microarrays are more variable in self-self hybridizations than 
others, leading to multiple false positives if one simply uses a differential 
expression value cutoff without sufficient replicates for statistical determinations. 
Moreover, because the variance estimates are sequence-specific, the use of Z-
scores based upon the variance estimate of all spots on the array is not always 
appropriate, and should not be used as the only criterion in determining 
differentially expressed genes. One caveat of using these stringent criteria is an 
increased probability of Type II statistical errors (false negatives). Still we believe 
this approach will identify those sequences which are most robustly and 
consistently modified. 
  For samples exhibiting significant differential expression in the amyloid-
containing and amyloid-free brain areas of transgenic animals, a one-way 
analysis of variance was performed   A planned post-hoc comparison of means 
(least significant difference) was used to determine if the expression was 
significantly different in the amyloid-containing vs. the amyloid-free brain areas 
for individual genes.  Each of the microarray clones that showed differential 
hybridization was unambiguously annotated by comparing its sequence (200-700 
bp) to GenBank using the BLAST 2 algorithm. 
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qRT-PCR 
Total RNA was prepared from dissected cerebellar and hippocampal 
tissue of 8 APP+PS1 mice and 8 non-transgenic littermates that were 18-19 
months old. Memory deficits and amyloid burden were established in the 
transgenic mice by radial arm water maze testing and immunohistochemical 
methods, respectively (Austin et al., 2003). Human temporal cortex (medial 
temporal gyrus; Brodmans area 21) and cerebellar tissue samples from 8 AD 
patients and 8 age-matched controls were pulverized by mortar and pestle on dry 
ice and 10-30mg of this powdered tissue was used to extract RNA. The 
homogenate from rotor-stator emulsification (Tissuemizer) of all tissues used 
were applied to RNeasy mini-spin columns (Qiagen) with on-column DNase 
treatment followed by elution with RNase-free water, according to the 
manufacturer’s specifications. All total RNA samples were then reverse 
transcribed with a 1:1 mixture of oligo dT (25ng/µl, Invitrogen) and random 
hexamers (2.5ng/µl, Invitrogen) to provide ample cDNA synthesis from both 18S 
rRNA (Schmittgen and Zakrajsek, 2000) and poly-adenylated mRNA. The final 
reverse transcription reaction included template (described below), 1M betaine 
(Sigma-Aldrich), providing more heat lability to nucleic acid and protein thermo-
stabilization, 1x cDNA first-strand synthesis buffer (Invitrogen), 7mM MgCl, 1mM 
dNTPs (Each A,G,C,T, Invitrogen), 40 units of RNaseOut (Invitrogen), 3mM DTT 
(Invitrogen), and 25 units of recombinant Superscript II reverse transcriptase (RT, 
Invitrogen). The reaction was brought to 20µl with water and then incubated for 
15 minutes at 25°C, followed by 30 minutes at 42°C and then 30 minutes at 
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60°C. The reaction was then heated at 95°C to denature the enzymes and stop 
the reaction. A standard curve was established within the reverse transcription 
reaction by adding total RNA (template) from an intra-experimental mouse or 
human RNA pool covering 3 logs (50, 20, 10, 5, 2, 1, 0.5 & 0.2ng) to separate 
wells. Two mass quantities (10 & 2ng) of total RNA from all samples being 
investigated were added to individual wells within the reverse transcription 
reaction for comparison to the standard curve. The RNA standard curve verifies 
the linearity of the RT-PCR reaction and controls for slight inefficiencies in the 
transcription and amplification steps of the procedure (below).  
  Primer pairs for qRT-PCR were generated to amplify ~100bp fragments of 
the gene of interest using the web-based applications Primer3 and the Oligo 
Toolkit at http://www.operon.com/. These oligos were tailored according to the 
species being analyzed. Primers were initially optimized using a PCR reaction 
followed by agarose gel analysis. If ethidium bromide staining revealed a single 
band, the primer concentrations were optimized by comparing at least three 
concentrations of each primer and noting which combination was most efficient at 
generating a PCR product (using SYBR green detection, see below), without 
producing signal in control wells lacking template. Experimental wells containing 
cDNA 25µl PCR reactions were run in triplicate consisting of a master mix 
containing 12.5µl of 2x SYBR Green Master Mix (Applied Biosystems), 0.25-4.5µl 
of forward and reverse primers in varied combinations, either 2µl of cDNA from 
an RT reaction or 2µl of water, to control for non-specific amplification due to self-
priming or contamination. The remainder of the 25µl volume was achieved by 
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adding water. 96-well plates were mixed by pipetting and then centrifuged. Two-
step PCR was run on the MJ Research Opticon (Boston, MA) as follows; 1 cycle 
of 95˚C for 15 minutes followed by 40 cycles of 95˚C for 15 seconds and 60-65˚C 
for 1 minute (primer annealing temperature is decided according to the Operon 
website calculations). This was followed by melt curve analysis beginning at 55˚C 
and increasing by 1˚C to 100˚C every 10 seconds, with fluorescence measured 
at every interval. None of the primer pairs demonstrated more than 1 peak of 
fluorescence as derived from the Opticon software, indicating a single gene 
product without primer-dimer formation.  
The target gene primers demonstrated similar amplification efficiencies as 
compared with 18S ribosomal RNA, allowing for quantitation of fold-change using 
18S signals to normalize the results for the quantity of starting RNA. The slope of 
the regression line for the standard curve determined efficiency, which varied by 
less than 5% for all amplicons.  Samples were run in triplicate, with both the 10ng 
and 2ng RT reactions represented for each. Standard curve samples were 
included on all plates to avoid errors due to minor plate-to-plate variations in 
amplification efficiency. The standard curve was calculated by plotting the 
threshold cycle (Ct, the point at which relative fluorescence exceeds a fixed value 
above background against the log nanogram quantity of RNA added to the RT 
reactions). A linear regression was performed and the slope-relating Ct to log 
RNA was calculated.  The average Ct for each sample was then used to 
determine the corresponding log ng of standard RNA using the slope of the 
standard curve.  These logarithmic values were then converted to a mass 
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quantity of standard RNA according to Ct. These mass values for the genes of 
interest were then divided by the 18S values of the same sample to determine 
fold-change in expression relative to the standard RNA pool.  For each region 
these fold change values for samples in the experimental (transgenic or AD) and 
control (non-transgenic or age-matched non-diseased) groups were analyzed for 
significance using 1-way ANOVAs.  The differential expression value between 
regions was similarly compared using one-way ANOVA. 
 
RESULTS 
The mice used for analysis were 17-18 month- old APP+PS1 transgenic 
mice that demonstrated impaired working memory performance compared to 
non-transgenic littermates (Morgan et al., 2000;Austin et al., 2003).  Different 
mice were used for microarray and qRT-PCR studies.  We first used a 
competitive hybridization approach to compare transcripts from transgenic 
mouse brain with matched non-transgenic tissues on cDNA microarrays.  Instead 
of assigning an arbitrary cut-off value to detect changes in regulation, the  
microarray analysis was based on multiple arrays with independent samples and 
statistical comparisons to determine those genes that were differentially 
expressed (see Methods). Using the rigorous criteria for the microarray analysis 
set forth above (see Methods), only five genes demonstrated significantly 
decreased expression in the amyloid-containing areas (hippocampus plus cortex 
for the array studies) of the transgenic animals (Table 1).  This group of genes 
included three genes that are essential for normal memory function  (Arc, Zif268, 
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Nur77/TR3) and two associated with neuronal/synaptic activity (Na+, K+ ATPase 
α III, calsyntenin). Except for Zif268 (see below) these reductions were restricted 
to amyloid-containing brain regions, and did not occur in regions from the same 
mice that were amyloid-free (cerebellum, striatum, brainstem in the array studies; 
Table 1), even though transgene expression was high in these regions (see 
below).    
Using qRT-PCR, we saw a similar pattern of specific amyloid-associated 
down-regulation for most of the genes in this group (Table 1).  Because of the 
50% reduction in the memory-associated genes Zif268 and Arc found with the 
microarray, we expanded the qRT-PCR analysis to include other genes related to 
synaptic function and memory processes (Figure 1).  This analysis showed that 
the transcript for the ionotropic glutamate receptor 1 (GluR1/AMPA1) was down-
regulated by 30% and the NMDA receptor subunit 2B (NR2B) RNA, known to be 
critical for cognitive processes (Tang et al., 1999), was decreased by 18% in 
amyloid-containing tissue (hippocampus alone for qRT-PCR studies). Expression 
of Homer-1a, which is a member of the Homer family of metabotropic glutamate 
receptor binding proteins (Brakeman et al., 1997) was reduced by 40%. Not only 
were these genes significantly down regulated in comparison to non-transgenic 
mice, they were also decreased significantly compared to the expression in 
amyloid-free tissue (cerebellum only for qRT-PCR studies) for the same animals 
(bracket above bars in Figure 1). Only one of the synaptic plasticity-related genes 
was significantly down-regulated in the amyloid-free region; Zif268 expression 
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measured by qRT-PCR was 18% lower in the cerebellum, which was still 
significantly less reduced than in the hippocampus (Figure 1). 
Not all of the synaptic plasticity genes we examined were changed in the 
transgenic mice.  Expression of synaptopodin (Mundel et al., 1997), which is 
argued to be involved in synaptic plasticity, was not changed, nor was GAP-43, 
also involved in synaptic plasticity and sprouting (Routtenberg et al., 2000), 
suggesting that not all synaptic-plasticity genes were modified in the transgenic 
animals. Other synaptic/neuronal markers were also expressed at normal levels 
in the transgenic animals, including synaptophysin, neurofilament-M, synapsin-1 
and synaptotagmin V.  The stability of these largely presynaptic markers was 
also observed in the results from the microarray study (Table 1).  
The microarray analyses revealed an up-regulation of a group of genes 
associated with inflammation and the acute phase response (Table 2). We 
quantified the up-regulation of three of these genes by qRT-PCR (GFAP, ApoE, 
and vimentin). Expression of glial fibrillary acidic protein (GFAP), an astrocyte-
specific intermediate filament, was increased by 6.3 fold in the APP+PS1 mice 
compared with non-transgenic littermates (Table 3). This reflects the astrocyte 
proliferation known to occur in the APP+PS1 animals (Holcomb et al., 1998) and 
is consistent with earlier immunoassay results measuring this protein (Gordon et 
al., 2002).   Additionally, another non-neuronal intermediate filament, vimentin, 
was up-regulated by more than two-fold and Apolipoprotein E (ApoE), another 
acute phase protein, was up-regulated to a lesser extent. These data are 
consistent with earlier reports describing reproducible glial activation and acute 
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phase reactivity in the APP+PS1 mice (Holcomb et al., 1998;Matsuoka et al., 
2001; Gordon et al., 2002). Most of these genes were unaffected  in the areas of 
the transgenic brain that were relatively free of plaques. However, a few of the 
genes were also upregulated in non-plaque-bearing regions (Table 3). Two of 
these genes were highly expressed because they contained sequence that was 
homologous to the sequence of the APP transgene. The APP transcripts on the 
microarray and the array sequences corresponding to the prion protein 5’ 
untranslated region (part of the transgene promoter construct (Hsiao et al., 1996) 
were elevated to the same extent in both the amyloid-containing and amyloid-
free regions.  Sequences on the microarray that encoded other regions of the 
prion gene were unaffected in transgenic animals (not shown). Notably, except 
for the transgenes and two others, the elevation in the amyloid containing regions 
was significantly greater than in the amyloid-free regions of the transgenic brain 
(Table 3, asterisks).  Coupled with the absence of up-regulation in amyloid-free 
regions for most of the genes in Table 2, it seems likely that the modest up-
regulation of several inflammation related genes in these amyloid-free regions 
reflects a lower level of generalized inflammation in these areas. 
We considered it critical to compare the expression of the synaptic marker 
genes in the mouse model with specimens from AD patients.  A previous 
microarray analysis (Loring et al., 2001) indicated that many markers of 
synapses were decreased in the amyloid-containing areas of AD brain. We 
extended this analysis by qRT-PCR measurements of a group of synaptic 
markers in the medial temporal gyrus of the cerebral cortex (MTG; Brodman's 
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area 21) and cerebellum of 8 AD patients and 8 cognitively normal age-matched 
controls.  As shown in Figure 2, all of the postsynaptic plasticity associated 
transcripts we analyzed were significantly under-expressed by more than 50% in 
the amyloid-containing cortical region, while the amyloid-free cerebellar tissue 
lacked any significant change in expression of the same genes, consistent with 
the relative sparing of the cerebellum in AD.  In this manner the pattern of 
changes in transgenic mice and AD cases was similar. However, in contrast to 
the observations we made for the mouse, in samples of AD MTG all of the other 
synaptic markers (synaptophysin, synapsin, synaptopodin, synaptotagmin, GAP-
43) were also reduced, as was  neurofilament M. Similar to the transgenic 
mouse, GFAP was elevated in the amyloid-containing region of the AD brain.  
Also similar to the mouse, there were no significant changes in the amyloid-free 
human cerebellum, coupling amyloid to the apparent loss of mRNA in the AD 
samples. These data are consistent with the considerable evidence showing 
neurodegeneration and synaptic loss in amyloid-containing regions of late stage 
AD. The results also highlight the similarities and differences between the severe 
loss of most cognitive function in AD and the relatively selective memory loss in 
amyloid-depositing transgenic mice which do not undergo neurodegeneration 
(Matsuoka et al., 2001).  
 
DISCUSSION 
The results of our microarray and qRT-PCR study show that the expression of 
several postsynaptic genes known to be integral for the establishment of LTP 
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and long-term memory, was selectively  down-regulated in the amyloid-
containing regions of memory-deficient APP+PS1 mice.  The amyloid-free 
regions of these transgenic mice do not  exhibit the same down-regulation. 
Additionally, several presynaptic genes that are often used as synaptic or 
neuronal markers are unaltered in these animals, similar to recent microarray 
findings in APP transgenic mice at an age preceding amyloid deposition (Stein 
and Johnson, 2002). These findings indicate that the failure of APP+PS1 mice to 
consolidate information for future recall may be precipitated by the amyloid 
dependent down-regulation of genes known to be critical for cognitive function. 
 Late phase LTP is thought to correspond to some forms of long-term 
memory consolidation because of the requirement for de novo protein synthesis 
for both processes (Morris, 1998). In APP transgenic mice, the formation of LTP 
is impaired in some, but not all studies (Chapman et al., 1999;Larson et al., 
1999;Fitzjohn et al., 2001). Recently it was found that oligomeric forms of the Aß 
peptide were particularly effective at impairing LTP when injected into the 
hippocampus in vivo (Walsh et al., 2002). Of particular relevance are previous 
observations that the plasticity-related genes we examined are essential for late 
phase LTP and long-term memory formation (Bolshakov et al., 1997;Ma et al., 
1999). Antisense oligonucleotides against Arc mRNA intracranially injected into 
rats eliminated both late phase LTP and long-term memory formation without 
affecting short-term forms of both processes(Guzowski et al., 2000). Mice with a 
targeted inactivation of Zif268 also lack the ability to express long-term synaptic 
and behavioral plasticity, although short-term forms of plasticity remain intact 
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(Jones et al., 2001). It has been reported that over-expression of the NR2B 
subunit leads to improved memory function (Tang et al., 1999), while intracranial 
injection of antisense oligonucleotides directed against NR2B mRNA inhibits LTP 
and cognitive function (Clayton et al., 2002). Additionally, there is a large amount 
of evidence suggesting an aggregation of AMPA receptors (GluRs) and 
metabotropic glutamate receptors (mGluRs) with NMDA receptors via proteins 
such as Homer and PSD95, further linking LTP with memory storage (Ango et 
al., 2000;Xiao et al., 1998). Homer-1a is elevated after synaptic activation and 
plays a role in targeting mGluRs to synapses  (Ango et al., 2000). Therefore all of 
these genes are known to play a role in cognitive ability, and their selective 
down-regulation in a mouse model of amyloid-associated memory deficits 
establishes them as possible candidates for pharmacotherapeutic approaches to 
AD. 
Although many of the genes known to influence memory were diminished 
in the APP+PS1 mice, there were several in our study that did not show down-
regulated expression. GAP-43, one of the unchanged genes, has been shown to 
improve cognitive function when over-expressed in transgenic mice (Routtenberg 
et al., 2000). Synaptopodin, another protein linked to plasticity (Mundel et al., 
1997;Deller et al., 2000;Yamazaki et al., 2001), is also stable in the amyloid-
containing regions of the APP+PS1 mouse brain.  These data imply that amyloid 
is selective in down-regulating only certain memory-associated genes, which are 
mostly postsynaptic.  There are several mechanisms which might account for 
these changes. One possibility is direct interaction of Aβ with one or more signal 
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transduction pathways. Alternatively, the regulation could be via an indirect 
pathway involving the acute phase response (e.g. cytokine effects secondary to 
amyloid-induced microglia activation).  The first idea is supported by the fact that 
several of the down-regulated genes are immediate early genes that can be 
induced by activating the ERK signaling cascade (Davis et al., 2000;Mazzucchelli 
et al., 2002). Aβ itself appears capable of modifying ERK signaling (Dineley et al., 
2001) potentially interfering with expression of these genes. Alternatively, as the 
induction of these IEGs is dependent upon synaptic activity, a generalized 
decrease in neuronal activity caused by Aβ might also explain the reductions in 
expression. There is also evidence supporting the indirect mode of regulation, 
since the glial reactions leading to the activation of inflammatory mediators 
correspond temporally to the period when memory loss is occurring (Gordon et 
al., 2002).  Dissociating between these mechanisms and identifying the specific 
components involved will also benefit development of rational pharmacotherapies 
for AD. 
We observed that many of the memory-associated genes were similarly 
deficient in the amyloid-containing regions of the human AD brain, confirming 
earlier reports from our group and others (Ginsberg et al., 2000;Loring et al., 
2001;Bi and Sze, 2002).   However, interpretation of this observation is 
complicated by the fact that multiple neuronal and synaptic marker genes were 
also under-expressed in the AD cortex we examined.  But our samples were from 
relatively late-stage AD, when amyloid deposition and neuronal dysfunction are 
extensive, and several reports indicate that widespread loss of synapses appears 
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to follow, not precede, loss of memory function.  In a detailed study of synaptic 
markers during the course of AD, it was reported that loss of synaptic markers 
only occurred in Braak stages 5 & 6, late in the disease when the pathology is 
most widespread (Mukaetova-Ladinska et al., 2000).  Another study (Tiraboschi 
et al., 2000) failed to detect changes in the synaptic markers synaptophysin or 
choline acetyl transferase in mild AD (MMSE = 20)   and a third report found that 
mildly demented individuals (CDR 0.5-1) had no change in synaptotagmin or 
GAP43, although a slight reduction in synaptophysin was found which worsened 
as the disease progressed (Masliah et al., 2001). A study by Minger et al found 
that only in AD cases that were severe (MMSE < 4) was there a significant 
reduction in choline acetyltransferase, synaptophysin, syntaxin or SNAP-25. 
None of these studies examined the synaptic plasticity markers that we observed 
to be decreased in the transgenic mice. In light of this evidence and our 
observations, we propose that the APP+PS1 mouse that 1) develops both 
forebrain-specific amyloid deposits and memory deficits, 2) suffers acute phase 
reactions in the brain, and 3) has decreased memory-associated gene 
expression without the loss of synaptic integrity markers, is likely to be an 
appropriate model for anterograde amnesias found in early stage AD.  
 Transgenic models for human disease have become a critical tool in the 
progression of therapeutic strategies to clinical trials. It is crucial, therefore, to 
validate the models for specific characteristics of the human disease. This report 
describes further characterization of a transgenic mouse model that constitutively 
expresses both the human APP and PS1 genes containing mutations that are 
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known to accelerate amyloid deposition and dementia in AD cases. The 
transcripts of several postsynaptic genes that are thought to be essential for the 
retention of memory and maintenance of LTP are specifically down-regulated in 
the cognitive areas of APP+PS1 mouse brain without the loss of expression of 
genes involved in synaptic function. When these genes were analyzed in late 
stage human AD temporal cortex, we found that the same memory-associated 
genes were down-regulated, but unlike the mouse, all markers for synaptic 
integrity and neuronal stability were also under-expressed. Along with the 
activation of glial cells and induction of acute phase reactants, the fact that the 
APP+PS1 mice deposit amyloid in the forebrain, develop anterograde amnesia 
and have altered expression of these memory-associated genes specifically in 
the cognitive domains of the brain suggests that some form of amyloid is 
facilitating the memory loss in these animals.  
These data also contribute to the growing pool of evidence that specific 
genes such as Arc, Zif268, NR2B, and Homer-1a are critical to normal memory 
function, and that their dysregulation may underlie the early phase of memory 
loss that occurs in AD.  Therefore it will be of great interest to evaluate methods 
to up-regulate these genes as potential therapeutic targets for use in early-stage 
AD and possibly other disorders involving memory deficiency. 
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TABLE 1.  Expression of neuronal genes in transgenic mice compared to nontransgenic mice  
(array and qRT-PCR data).   
Array Data 
Percentage of nontransgenic mean 
± SEM.  (z-score in parentheses) 
qRT-PCR Data 
Percentage of 
nontransgenic mean ± 
SEM 
Marker 
mRNA Protein Function 
Amyloid-
Containing Area 
Amyloid-Free 
Area 
Amyloid-
Containing 
Area 
Amyloid-
Free 
Area 
Arc LTP-associated structural  64 ±  3* (2.8) 108 ± 6 (0.4) 48  ± 10* 97 ±  5 
Calsyntenin Postsynaptic Ca(2+) signaling 64 ± 3* (2.8) 79 ± 5 (1.33) 99 ±  9 nd 
Gap43 Neuritic growth, plasticity 115 ± 7 (0.75) 87 ± 7 (0.75) 104 ± 10 94 ± 4 
GAPDH Energy metabolism  91 ± 4 (0.49) 97 ± 1 (0.15) 82 ± 7 nd 
GluR1 Postsynaptic receptor  102 ± 2 (0.1) 105 ± 3 (0.25) 70 ± 10* 95 ± 6 
Homer-1a LTP-associated, regulatory nd nd 60 ± 7* 95 ±  9 
Na, K ATPase αIII Neuronal ion gradient, transmission 66 ±  4* (2.6) 77 ±  3 (1.5) 57 ± 4* 99 ±  5 
NAB2  LTP-related, regulatory nd nd 115 ± 7 nd 
Neurofilament M Neuronal structural 103 ± 1 (0.15) 104 ± 1 (0.20) 82 ± 7 nd 
“*” significantly different from nontransgenic mice at P<0.05 
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TABLE 1 (CONTINUED) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“*” significantly different from nontransgenic mice at P<0.05 
Array Data 
Percentage of nontransgenic mean 
± SEM.  (z-score in parentheses) 
qRT-PCR Data 
Percentage of 
nontransgenic mean ± 
SEM 
Marker 
mRNA Protein Function 
Amyloid-
Containing Area 
Amyloid-Free 
Area 
Amyloid-
Containing 
Area 
Amyloid-
Free 
Area 
NR2B Receptor implicated in memory consolidation nd nd 82 ± 5* 99 ± 5 
Nur-77 LTP-associated, regulatory 61 ± 4* (3.2) 77 ± 1 (1.5) nd nd 
Synapsin Presynaptic vesicle-associated 71 ± 8* (2.0) 92 ± 2 (0.4) 103 ± 7 82 ± 18 
Synaptophysin Presynaptic vesicle-associated 126 ± 8 (1.3) 91 ±  4 (0.5) 101 ± 5 98 ± 5 
Synaptopodin LTP-associated structural nd nd 91 ± 5 nd 
Synaptotagmin 5 Presynaptic vesicle-associated 98 ± 4 (0.1) 106 ± 2 (0.3) 106 ± 19 nd 
Syntaxin  Presynaptic vesicle-associated nd nd 94 ± 7 nd 
Zif268 LTP-associated, regulatory 60 ± 5* (3.3) 88 ± 8 (0.68) 45 ± 8* 82 ± 3* 
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TABLE 2. Genes that are up-regulated in amyloid-containing areas of transgenic 
mice brains compared to the same areas of nontransgenic mice brains 
(microarray data). 
Function and Location Gene Name 
Percentage of 
nontransgenic mean ± SEM 
(z-score in parentheses) 
Alpha-1 type III collagen 162 ± 7* (3.3) 
Alpha-fibrinogen Fga 368 ± 46* (13.6) 
Beta-2-microglobulin 203 ± 9* (5.4) 
Beta-5 integrin 190 ± 11* (4.7) 
Beta-galactoside-binding lectin 177 ± 14* (4.1) 
Cd63 193 ± 16* (4.9) 
Complement component C1q alpha chain 289 ± 27* (9.6) 
Complement component C1q beta chain 200 ± 16* (5.2) 
Complement component C4 297 ± 22* (10.1) 
Histidine-rich glycoprotein 172 ± 13* (3.8) 
Ig heavy chain VDJh2 region 160 ± 10* (3.2) 
Lysozyme 183 ± 8* (4.4) 
MHC class I 166 ± 6* (3.5) 
MHC class I A1(f) alpha chain RT1.A1(f) 182 ± 8* (4.3) 
Transferrin 178 ± 10* (4.1) 
Secreted/ 
Cell Surface 
Tyrosine kinase binding protein 254 ± 6* (7.9) 
Glial fibrillary acidic protein 483 ± 64* (19.4) 
Cytoskeletal 
Vimentin 181 ± 14* (4.3) 
Cathepsin D 253 ± 32* (7.9) 
Cathepsin S 248 ± 21* (7.6) 
Inflammation 
Lysosomal 
Cathepsin Y 187 ± 22* (4.6) 
 
“*” All entries are significantly different from amyloid-containing regions of non-
transgenic mice at P < 0.05
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TABLE 2 (CONTINUED). 
 
Function and Location Gene Name 
Percentage of 
nontransgenic mean ± SEM 
(z-score in parentheses) 
Acyl-CoA binding protein 166 ± 6* (3.5) 
Apolipoprotein D 159 ± 10* (3.2) 
Apolipoprotein E 160 ± 4* (3.2) 
Lipid 
binding 
Niemann Pick type C2 180 ± 12* (4.2) 
Alpha-D-mannosidase 162 ± 7* (3.3) 
Cystathionine beta-synthase 377 ± 22* (14.1) 
Kelch-like 1 189 ± 15* (4.7) 
Mitochondrial Epsilon-trimethyllysine 2-
oxoglutarate dioxygenase
175 ± 21* (4.0) 
Intracellular 
Serine protease inhibitor  161 ± 21* (3.3) 
SPI-2 serine protease inhibitor 176 ± 14* (4.0) 
Acute-phase 
reaction 
Secreted/ 
Cell 
Surface Thyroid hormone receptor alpha  618 ± 73* (26.1) 
“*” All entries are significantly different from amyloid-containing regions of non-
transgenic mice at P < 0.05 
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TABLE 3.  Genes that are up-regulated in both amyloid-containing brain regions and amyloid-free 
 brain regions of transgenic mice (array and qRT-PCR data). 
Array Data 
Percentage of nontransgenic mean 
± SEM 
qRT-PCR Data 
Percentage of 
nontransgenic mean ± 
SEM Marker RNA 
Amyloid-
Containing Area 
Amyloid-Free 
Area 
Amyloid-
Containing 
Area 
Amyloid-
Free Area 
APP 192 ± 7 (4.8) 209 ± 7 (5.7) nd nd 
Transgene 
Prion protein (UTR) 223 ± 15 (6.4) 242 ± 14 (7.3) nd nd 
Apolipoprotein E 160 ± 4 (3.2) 171 ± 10 (3.8) 156 ± 16 nd 
Alpha-1 type III collagen 162 ± 7 (3.3) 167 ± 12 (3.6) nd nd 
Complement component C1q 
alpha chain 
289 ± 27* (9.7) 182 ± 18* (4.3) nd nd 
Complement component C4 297 ± 22* (10.1) 154 ± 8* (2.9) nd nd 
Cystathionine beta-synthase 377 ± 22* (14.1) 194 ± 16* (4.9) nd nd 
GFAP 483 ± 64 *(19.4) 182 ± 13* (4.3) 629 ± 115  nd 
Thyroid hormone receptor alpha 618 ± 73*(26.1) 234 ± 24* (6.9) nd nd 
Inflammation 
Tyrosine kinase binding protein 254 ± 6* (7.9) 161 ± 7* (3.3) nd nd 
“*” Data in BOLD are significantly more highly expressed in amyloid-containing regions than  
amyloid-free regions of  transgenic mice. nd: not determined 
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FIGURE 1. Gene expression profile of transgenic mice in amyloid-containing and 
amyloid-free brain regions by qRT-PCR. 
The differential expression (transgenic expression relative nontransgenic 
expression) is presented  for genes that are down-regulated in transgenic 
animals and primarily postsynaptic (left half of figure) and those that are stably 
expressed and largely presynaptic (right half of figure). The relative expression in 
the amyloid-containing region (hippocampus; black bars) and amyloid-free region 
(cerebellum; gray bars) are shown when both regions were analyzed.  These 
regions are also designated in the line to the right of "Aß plaques" with a "+" 
beneath the bar indicating amyloid-containing region or a "-" beneath the bar 
indicating an amyloid-free region. Following qRT-PCR, each gene transcript level 
for each sample is first normalized to the 18S RNA level measured from the 
same reverse transcription.  For each region, relative expression was determined 
by dividing each transgenic value by the average of the non-transgenic values. 
The relative expression values for the amyloid-containing and amyloid-free 
regions could also be compared statistically to determine if the reduction in 
expression was different in the two structures. The values represented in this 
figure are the mean + SEM . We did not determine cerebellum measurements for 
several genes that were unaffected in the hippocampus of the transgenics, as 
indicated by "N.D." in the place of the bar on the figure. “*” indicates significant 
differences between APP+PS1 mice and non-transgenic littermates (p < 0.05). 
"†" above the bracket indicates transgene associated down-regulation to a 
greater extent (P < 0.05) in the amyloid-containing than  the amyloid-free regions. 
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FIGURE 2. Gene expression profile of Alzheimer disease tissue in amyloid-
containing and amyloid-free brain regions by qRT-PCR. 
The differential expression (Alzheimer relative to age-matched normals) is 
presented  for genes that are primarily postsynaptic (left half of figure) and those 
that are primarily presynaptic (right half of figure). The relative expression in the 
amyloid-containing region (temporal cortex; area 21; black bars) and amyloid-
free region (cerebellum; gray bars) are shown when both regions were analyzed. 
These regions are also designated in the line to the right of "Aß plaques" with a 
"+" beneath the bar indicating amyloid containing region or a "-" beneath the bar 
indicating an amyloid-free region. Following qRT-PCR, each gene transcript level 
for each sample is first normalized to 18S RNA measurements from the same 
reverse transcription.  For each region, relative expression was determined by 
dividing each Alzheimer sample value by the average of the age-matched normal 
values. The relative expression values for the amyloid-containing and amyloid-
free regions could also be compared statistically to determine if the reduction in 
expression was different in the two structures. The values represented in this 
figure are the mean + SEM. We did not determine cerebellum measurements for 
several genes as indicated by "N.D." in the place of the bar on the figure. “*” 
indicates significant differences between Alzheimer and age-matched normals (p 
< 0.05).    "†" above the bracket indicates disease associated down-regulation to 
a greater extent (P < 0.05) in the amyloid-containing than the amyloid-free 
regions.
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ABSTRACT 
 Mice transgenic for mutated forms of the amyloid precursor protein (APP) 
plus presenilin-1 (PS1) genes (APP+PS1 mice) gradually develop memory 
deficits which correlate with the extent of amyloid deposition. The expression of 
several immediate-early genes (IEGs: Arc, Nur77 and Zif268) and several other 
plasticity-related genes (GluR1, CaMKIIα and Na-K- ATPase αIII) critical for 
learning and memory was normal in young APP+PS1 mice preceding amyloid 
deposition, but declines as mice grow older and amyloid deposits accumulate. 
Gene repression was less in APP+PS1 mouse brain regions that contain less Aβ, 
and in APP mice compared to APP+PS1 mice, further linking the extent of 
amyloid deposition and the extent of gene repression. Critically, we 
demonstrated that amyloid deposition led specifically to impaired induction of the 
IEGs with no effects on basal expression using exposure to a novel environment 
30 minutes prior to sacrifice to induce IEGs. These data imply that Aβ deposition 
can selectively reduce expression of multiple genes linked to synaptic plasticity 
and provides a molecular basis for memory deficiencies found in transgenic APP 
mice and, most likely, in early stage Alzheimer's disease (AD). Presumably, 
pharmacological agents blocking the Aβ-related inhibition of gene expression will 
have benefit in AD. 
Keywords: Alzheimer’s, Induction, Immediate-early genes, Transgenic, Amyloid, 
Plasticity 
Running Title: Amyloid Suppresses Memory-Related Gene Induction 
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INTRODUCTION 
Mutations in the amyloid precursor protein (APP) and presenilin-1 (PS1) 
genes accelerate Aβ deposition and lead to an aggressive form of early-onset 
Alzheimer’s disease (AD; Selkoe 2001) Mice transgenic for the mutant forms of 
the human APP (Hsiao et al. 1996) and PS1 (Duff et al. 1996) genes have been 
bred to generate a viable doubly transgenic mouse presenting accelerated 
amyloid pathology (APP+PS1 mice; Holcomb et al. 1998). Despite the lack of 
intracellular fibrillary tangles and neuronal degeneration, these mice do exhibit 
anterograde amnesia and increased neuro-inflammation with age, providing a 
good model for the study of amyloid-associated memory loss at a stage of 
pathology similar to that in early AD (Mukaetova-Ladinska et al. 2000;Morgan et 
al. 2000;Gordon et al. 2002;Arendash et al. 2001). 
Based on work involving DNA microarray comparisons, we previously 
described the down-regulation of several genes in 18+ month-old APP+PS1 mice 
using quantitative real-time RT-PCR (qRT-PCR; Dickey et al. 2003). Of particular 
interest was a panel of down-regulated immediate early genes (IEGs) implicated 
in memory function, such as Zif268 (Hall et al. 2000;Miyashita et al. 1998) and 
activity-regulated cytoskeletal-associated protein (Arc; Guzowski et al. 2001). We 
demonstrated that several more synaptic genes were also selectively down-
regulated in the amyloid-containing hippocampus of APP+PS1 mice (e.g. the 
ionotropic glutamate receptor 1 (GluR1) and Na, K ATPase αIII), while other vital 
synaptic mRNAs remained unchanged (e.g. synaptophysin and growth-
associated protein 43 (Gap43)).  
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Our earlier work found that in most instances, gene expression in 
APP+PS1 mice was normal in the amyloid free cerebellum. Here, we describe 
additional studies to test the linkage between amyloid deposition and 
suppression of these genes, and address whether the diminished IEG expression 
is due to reduced basal expression or impaired induction. 
 
MATERIALS & METHODS 
 Mice were bred in our facility and genotyped using previously described 
methods (Gordon et al. 2002). For most experiments, each mouse was 
individually transported out of the vivarium to a holding room 30 minutes before 
sacrifice. Mice were deeply anesthetized with pentobarbitol (100 mg/kg) and 
perfused transcardially with 0.9% saline. Brains were quickly removed and 
regions dissected and frozen on dry ice. We have shown previously that the 
behavior and amyloid burden of 18 month-old APP+PS1 mice were significantly 
different from the non-transgenic littermates used for these studies (Austin et al. 
2003). 
IEGs were induced by exposure to a novel environment. Fourteen mice 
(six 18 month-old APP+PS1 and eight age-matched non-transgenic littermates) 
were handled and weighed for three consecutive days to acclimate them to the 
holding room and the experimenter. On the fourth day, the mice were placed into 
a 0.6m x 0.6m Plexiglas open field containing objects for the mice to investigate 
or crawl through for 5 minutes. All mice actively explored this environment and no 
differences between transgenic and non-transgenic mice could be discerned in 
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the notes taken by the experimenter. After 5 minutes, the mice were placed into a 
new cage located in a different room from their home cage for 30 minutes to 
avoid disturbing other mice. Following this 30 minute period, mice were killed as 
described above. The novel environment was cleaned with 30% ethanol between 
mice. To ascertain basal expression levels of IEGs, 14 other mice (six 18 month-
old APP+PS1 and eight age-matched non-transgenic littermates) from the same 
cohort were removed from their home cage and killed with no delay. 
Total RNA was prepared from dissected brain tissue of APP only, PS1 
only and APP+PS1 mice along with non-transgenic littermates as previously 
described (Dickey et al. 2003). Briefly, total RNA samples were reverse 
transcribed (RTed) with MMLV reverse transcriptase and 1M betaine. A standard 
curve was established by transcribing increasing amounts of total RNA (covering 
3 logs) from an RNA pool compiled from all samples used in that experiment. 
Two mass quantities (10 & 2ng) or, in later experiments, a single mass quantity 
of 5ng of total RNA from each sample were RTed for comparison to the standard 
curve.  
Primer pairs for qRT-PCR were generated from the web-based 
applications Primer3 and the Oligo Toolkit (Operon). Experimental wells 
containing 25µl PCR reactions were run in triplicate in 96-well plates. Two-step 
PCR was run on the MJ Research Opticon (Boston, MA) as follows; 1 cycle of 
95˚C for 15 minutes followed by 40 cycles of 95˚C for 15 seconds and 60-65˚C 
for 1 minute. All primer pairs amplified a single peak of fluorescence by melt 
curve analysis. The standard curve was calculated by plotting the threshold cycle 
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(Ct) against the log nanogram (ng) quantity of RNA added to the RT reactions. 
PCR efficiency varied by less than 5% for all amplicons. A linear regression was 
performed and the slope, relating Ct to log ng RNA, was calculated, and 
converted to a mass quantity of standard RNA. These mass values for the genes 
of interest were then divided by 18S ribosomal RNA mass values of the same RT 
reaction to determine fold-change in expression relative to the standard RNA 
pool.  We chose 18S rRNA as the endogenous control gene based on empirical 
data of our own and results from others (Schmittgen and Zakrajsek 2000) 
indicating that other commonly used house-keeping genes such as β-actin and 
GAPDH have more variable expression in tissue, particularly brain, while 18S 
remained steady. These fold change values for samples in the experimental and 
control groups were analyzed for significance using 1-way ANOVAs (Dickey et al. 
2003). For the mice in the behavioral induction study a 2-way ANOVA was 
performed with the main variables being genotype and induction state. 
 
RESULTS 
Quantitative RT-PCR analysis of hippocampal tissue from APP+PS1 mice 
at 2, 6 and 18 months of age revealed decreases in specific mRNA transcripts 
with increased amyloid accumulation. At 2 months of age, prior to development 
of cerebral amyloid, no loss of mRNA expression was seen for any marker (Figs 
1A & B). However, by 6 months of age, the IEGs Nur77 (a nuclear orphan 
receptor), Arc and Zif268 were significantly under-expressed by 35, 40, and 22%, 
respectively, compared to non-transgenic littermates (Fig 1A). By 18 months, in 
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addition to further reduced IEG expression, GluR1, calcium/calmodulin kinase IIα 
(CaMKIIα) and Na, K ATPase αIII mRNA expression was significantly reduced by 
20-30% (Fig 1B). Synaptophysin and Gap43 remained unchanged throughout 
the lifespan of the transgenic mice. The findings herein also revealed two distinct 
patterns in gene regulation. The early decrease in IEG expression at 6 months in 
the APP+PS1 mice (Fig 1A) is contrasted by the later reduction in the more 
constitutively expressed plasticity genes GluR1, CaMKIIα and Na, K ATPase αIII 
seen at 18 months (Fig 1B). Figure 1C was generated by averaging the individual 
sample percent reduction values for each gene, then averaging these according 
to IEG, plasticity-related or non-changing synaptic category and doing one-way 
ANOVA on these values to determine significance. This figure demonstrates that 
a significant reduction at 6 months is only seen with the IEGs when analyzed in 
this manner, while at 18 months both IEG and plasticity-related gene expression 
was significantly reduced. 
To further understand the relationship between amyloid deposition and 
mRNA expression, we investigated the gene expression of 18 month-old singly 
transgenic APP or PS1 mice compared to mice expressing both APP+PS1 
transgenes. The amyloid-free PS1 transgenic mice had no changes in 
expression of any genes (Fig 2). However, the singly transgenic APP mice 
exhibited significant 30-40% loss of the IEGs Nur77, Arc and Zif268, without 
significant loss of the more constitutively expressed synaptic proteins GluR1, 
CaMKIIα and Na, K ATPase αIII (Fig 2).  
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A regional analysis was then performed on 18 month-old APP+PS1 mice, 
comparing gene expression levels in the hippocampus, posterior cortex and 
caudate nucleus (striatum). In the posterior cortex, APP+PS1 mice had a 
significant reduction in the IEGs, however the other plasticity-related genes, 
GluR1 and Na, K ATPase αIII remained unchanged (Fig 3). CaMKIIα was also 
significantly reduced, but not to the same extent as in the hippocampus (Fig 3). 
Caudate nucleus analysis revealed a similar pattern of expression; significantly 
reduced IEGs (25-35%) without reductions in the other plasticity-related genes 
(Fig 3). For all genotypes and brain regions, Gap43 and synaptophysin 
expression was unaltered (Figs 2& 3).  
To determine whether the reduction of the IEGs in the memory-deficient 
APP+PS1 mice was a result of lower basal expression level or decreased 
experience-dependent induction, we exposed 18 month-old APP+PS1 mice and 
their non-transgenic littermates to a novel environment for 5 minutes followed by 
30 minutes in a new cage. This manipulation provided the means to increase IEG 
expression, resulting in increased representative mRNA levels (see methods 
above). For the non-induced (basal) control groups, additional 18 month-old 
APP+PS1 mice and their non-transgenic littermates were taken from their home 
cage and rapidly killed. Upon analyzing the hippocampi of these mice by qRT-
PCR, we found that there was a significant 2.5 fold induction of IEGs in our 
behavioral paradigm in non-transgenic mice (Fig 4). This induction was 
significantly blunted by half for Arc and Nur77 in the APP+PS1 mice compared to 
induced non-transgenic littermates (Fig 4). The basal expression of the IEGs was 
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nearly identical in the two genotypes (Fig 4). Zif268 expression was also induced 
significantly by the environmental novelty, but suppression of its induction in 
APP+PS1 mice was not statistically significant. The other plasticity-related 
genes, GluR1, CaMKIIα and Na, K ATPase αIII were not induced by exposure to 
the novel environment. However these genes did have significantly reduced 
expression when analyzed by genotype, while Gap43 and synaptophysin 
remained unaffected by genotype or exposure to a novel environment (Table 1).  
Glial fibrillary acidic protein (GFAP) mRNA increased in the hippocampi of 
APP+PS1 mice. At 2 months, GFAP was unchanged, by 6 months it was 
increased by 80% and at 18 months levels increased to over 300% that of non-
transgenic littermates (data not shown), demonstrating the potential role for glial 
cells in the pathogenesis of amyloid-associated dementias and confirming earlier 
ELISA and histochemical results in APP+PS1 mice (Morgan et al. 1991;Gordon 
et al. 2002). We have also increased the breadth of our investigations into gene 
expression by analyzing many more genes, finding that several more remain 
unaltered in the 18 month-old APP+PS1 hippocampus compared to non-
transgenic littermates. These include Ha-Ras, Rheb, Shank3, synapsin, 
microtubule-associated protein 2 (MAP2), the Na, K ATPase γ subunit and the 
two metabotropic glutamate receptors, mGluR1 and mGluR5. These findings 
reiterate the selectivity of gene dysregulation associated with either amyloid 
deposition itself or its subsequent deleterious effects on the brain. 
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DISCUSSION 
Post-mortem brain tissue from AD patients is riddled with amyloid plaques 
comprised of Aβ peptide polymers and intracellular neuro-fibrillary tangles of 
hyperphosphorylated tau filaments. Neuron loss and gliosis are also evident. The 
cognitive impairments of the disease could be attributed to any combination of 
these pathologies, and recent evidence supports each of these components. The 
development and subsequent usage of transgenic animal models expressing 
genes known to produce AD-like pathology have provided a way to elucidate the 
contributions of these individual pathological features. Here, we have utilized the 
memory-deficient APP+PS1 mouse model to analyze expression of genes that 
appear to be essential for the formation of memories. Using qRT-PCR, we have 
found that as amyloid becomes reliably detectable in the brains of the APP+PS1 
mice (6 mos.), IEGs begin to realize decreased expression. As amyloid burden 
increases, resulting in further gliosis and onset of memory loss, several other 
more constitutively expressed genes critical for plasticity and memory function 
are significantly reduced. Perhaps of greatest significance here is the finding that 
the induction of the IEGs was significantly impaired, indicating that the triggering 
mechanism for their rapidly increased expression is being inhibited somehow in 
these mice that develop amyloid. These data provide strong support for the 
hypothesis that amyloid, itself, impairs the induction and expression of genes 
thought to be essential for retaining newly acquired information. 
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Our first indication that amyloid might repress genes essential for memory 
came via a microarray study (Dickey et al. 2003). Intrigued by the novelty of the 
idea that amyloid may suppress molecular mechanisms for memory, independent 
of neuron or synapse loss, we examined other memory associated genes and as 
of this writing have found 11 that are down-regulated. For these studies, we 
chose a representative panel of these down-regulated genes associated with 
LTP and memory consolidation, 3 of which are immediate early (inducible) genes 
(Arc, Nur77 & Zif268) and 3 with more constitutive expression (Na, K ATPase 
αIII, GluR1 and CaMKIIα). Mice receiving antisense oligonucleotides targeting 
the mRNA of Arc, an IEG that is translated at the synapses (Lyford et al. 1995), 
have disrupted LTP maintenance and demonstrate impaired long-term memory 
(Guzowski et al. 2000). Nur77 mRNA, also an IEG product, is the transcript for 
an orphan thyroid hormone receptor that is dramatically increased in response to 
several excitotoxic stimuli (Watson and Milbrandt 1989;St Hilaire et al. 2003). 
Zif268 is a zinc finger transcription factor that is rapidly up-regulated in the 
hippocampus of rats after exposure to a novel stimulus (Hall et al. 2000) and by 
water maze training (12). Additionally, homozygous Zif268 knockout mice exhibit 
long term-term memory deficits (Jones et al. 2001) underscoring the critical 
nature of this gene to proper cognitive function. The Na, K ATPase αIII subunit, 
when inhibited by oubain, is known to disrupt memory consolidation (Watts and 
Mark 1971;Mark and Watts 1971). Recent reports have implicated the ionotropic 
glutamate receptor GluR1 (AMPA1) as essential for various forms of synaptic 
plasticity and memory retention (Schmitt et al. 2003;Lee et al. 2003). CaMKIIα, is 
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also thought to be critical for memory retention, as evidenced by mice transgenic 
for activated forms of the protein having impaired memory retention (Mayford et 
al. 1995;Mayford et al. 1996). Expression of both the growth associated protein, 
Gap43, a gene important for growth cone formation as well as memory 
(Routtenberg et al. 2000), and synaptophysin, a protein widely used as a marker 
for nerve terminals, remains unchanged in the APP+PS1 mouse brain. Thus, not 
all genes involved in synaptic function or plasticity are down-regulated by Aβ 
deposits. 
To understand the contribution of amyloid to the dysregulation of gene 
expression in the APP+PS1 mice we analyzed hippocampal tissue from 2 month-
old mice, an age prior to amyloid deposition (Gordon et al. 2002), 6 month-old 
mice, when amyloid deposits are just beginning to form, and 18 month-old mice, 
when there is considerable amyloid in the forebrain (Gordon et al. 2002). 
Critically, the stable expression of all genes analyzed at 2 months (Fig 1), an age 
when APP and PS1 over-expression is present, but amyloid deposits have not 
yet appeared, argues that transgene expression per se is not the cause of the 
reduced expression. It is the accumulation of amyloid that appears to be 
regulating expression in such a way that some genes, predominately the IEGs, 
are diminished when amyloid deposits are still low (6 mos.) while others (e.g. 
GluR1 and Na, K ATPase αIII) are only affected when amyloid deposition is 
substantial (18 mos.). CaMKIIα expression is significantly decreased at 6 months 
although not to the same degree as the IEGs. This could possibly indicate that 
CaMKIIα is one of the first genes being affected by the presence of excess 
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amyloid in the brain, which is significant due to its involvement in the calcium 
signaling cascade thought to mediate receptor activated transcription (Blanquet 
et al. 2003). As summarized in figure 1C, these findings provide evidence that 
slightly reduced IEG expression is not sufficient to cause memory impairments, 
but, assuming that protein expression of these genes follows that of their mRNA, 
the additional down-regulation of these more constitutively expressed plasticity-
related genes, as detected at 18 mos., may be necessary to disrupt memory. 
This emphasizes the robustness of mnemonic processes (or the lack of 
sensitivity of behavioral tests), as only when partial inhibition of the expression of 
multiple genes are present in aggregate are memory deficits readily apparent.  
The APP only mice have roughly one third of the Aβ deposition as 
APP+PS1 mice (Jaffar et al. 2001), while the PS1 mice resemble non-transgenic 
mouse brain when analyzed for amyloid burden and amyloid associated 
pathogenesis. Our findings in figure 2 reveal that the singly transgenic APP mice 
also have reduced IEG expression without reductions in the other plasticity-
related genes, while the PS1 singly transgenic mice do not have reductions in 
either set of genes. This is consistent with the selective impairment of IEG 
expression found at 6 mos.  
We had previously shown that gene expression in the cerebella of 
APP+PS1 mice, a region without detectable amyloid levels, remained unchanged 
when compared with non-transgenic littermates (Dickey et al. 2003). 
Subsequently, we analyzed two additional regions of the forebrain in 18 month-
old APP+PS1 mice; posterior cortex, a region with fewer amyloid plaques than 
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the hippocampus,  and the caudate nucleus, a brain region that does not 
accumulate fibrillar amyloid plaques, yet has abundant diffuse Aβ (Gordon et al. 
2002). Interestingly, upon analysis of both of these regions, we found that like the 
APP singly transgenic mice and the 6 month-old APP+PS1 mice, only the IEGs 
were significantly under-expressed. Similar to the 6 month-old APP+PS1 mice, 
CaMKIIα was slightly down-regulated in the posterior cortex but not as 
dramatically as in the hippocampus. Again, this is consistent with the relative 
amyloid burden associated with these two conditions. Perhaps most significant is 
the finding that the caudate nucleus, which only contains diffuse Aβ, still has 
reduced IEG expression. This further implicates Aβ itself, rather than a mediator 
of neuro-inflammation, as the precipitator of this mRNA reduction. These findings 
again argue that the IEGs are very sensitive to the presence of amyloid, possibly 
indicating a direct interaction of the amyloid peptide with some mechanism 
regulating the expression of these genes.  
One final critical issue in this investigation was the nature of the reductions 
seen in IEG expression. These genes are expressed at low levels when mice are 
in a resting state. However, upon induction by some stimulus (e.g. maximal 
electroconvulsive shock (MECS; Cole et al. 1990) or a novel environment 
(Guzowski et al. 2001) there is a rapid and robust increase in their expression, at 
which point they have dramatic effects on synapse structure and properties. This 
increase is transient so that within minutes to hours, some IEGs return to their 
basal expression level. By using a novel environment, in which mice were 
allowed to investigate several new objects for 5 minutes, we were able to 
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demonstrate a significant induction of the IEGs Arc, Nur77 and Zif268. We 
selected a 30 minute duration as the  time point because previous studies have 
shown that Arc and Nur77 reach a maximal level of expression by 30 minutes 
and begin to return to basal levels after 1 hour (Lyford et al. 1995;Tang et al. 
1997). We felt that genes that were induced maximally would provide us the 
greatest opportunity to see any significant reductions in their expression. 
Previous studies have indicated that zif268 mRNA has a slightly greater half-life 
than other IEG RNAs (Guzowski et al. 2000;Guzowski et al. 2001) which would 
effectively increase basal levels, making it more difficult to detect differences due 
to a single behavioral event, possibly explaining the reason we were unable to 
see significant reductions in its expression. We had suspected that our standard 
transport and handling procedures prior to killing the mice were sufficient to 
induce the IEGs. Anticipating this, our standard protocol is to retrieve each 
mouse from the vivarium 30 minutes before pentobarbitol injection. The finding 
that only the induction of these genes was impaired in APP+PS1 mice confirms 
these suspicions. These observations emphasize the need to control the 
conditions leading up to euthanasia in studies of gene expression in brain.  
These data, when taken together with the findings that Aβ is precipitating 
reductions in gene expression, indicate that in amyloid-depositing APP+PS1 
mice, the ability to induce IEG expression is suppressed. This suppression may 
be a direct effect of Aβ on a receptor altering signal transduction cascades 
(possibly the Ras/MAPK pathway or the Ca++ signaling cascade (Dineley et al. 
2001)). Alternatively, Aβ deposition may impair increases in general synaptic 
 75
activity presumed to result from exposure to environmental novelty, leading to 
less induction of these activity dependent IEGs. The diminution of Na, K ATPase 
activity may permit normal resting activity in neurons, but lead to failure when 
demands for ion pumping increase with elevated synaptic activity. Another 
possibility remains that these events are secondary to increased inflammation 
associated with glial activation, particularly given the considerable effects that 
cytokines can have on gene expression. However, at least for the IEGs this 
seems unlikely, as microglial activation and cytokine production are low in 6 
month APP+PS1 mice, when the IEGs are already realizing significant decreases 
(Fig 1A & C; (Gordon et al. 2001;Benzing et al. 1999;Mehlhorn et al. 2000). 
Ultimately, the data presented here point to Aβ, or some direct effect of its 
presence in the brain, as the causal agent for suppressed induction of IEG 
expression.  
The failure to identify reduced expression of rheb in APP+PS1 mouse 
hippocampus provides an example of one IEG that does not seem to be 
influenced by the presence of Aβ. Shank3, involved in formation of the post-
synaptic density (Boeckers et al. 2002), along with calsyntenin-1 and 
synaptopodin (Dickey et al. 2003), also remain unchanged in the APP+PS1 
mouse, eliminating the possibility of a generalized but exclusive loss of post-
synaptic mRNAs, with axon terminals remaining intact and functional. Also, the 
two dendritic metabotropic glutamate receptors, mGluR1 and mGluR5, that have 
been linked to memory formation and LTP-maintenance (Riedel et al. 2000), do 
not exhibit significant decreases (Petersen et al. 2002). Other genes with 
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unchanged expression are MAP-2, thought to propagate growth cone formation 
of the axon (Gordon-Weeks 1991) and the Na, K ATPase γ subunit, which 
modulates the activity of the ATPase α subunit (Crambert and Geering 2003), 
demonstrating a specific reduction in the catalytic α subunit expression level. The 
stability of these other markers emphasizes the significance of those genes that 
do suffer from amyloid-related repression. 
  The recent finding by Hock et al. that vaccination with the amyloid peptide 
stabilized and, in some cases, improved cognitive ability in humans suffering 
from AD (Hock et al. 2003), argues that Aβ itself likely plays in the development 
of memory dysfunction in AD beyond the effects on neuronal and synapse loss. 
The data presented here provide new evidence to support the idea that Aβ 
impedes the induction of genes critical for synaptic plasticity. The APP+PS1 
transgenic mouse model, therefore, provides a means with which to understand 
how amyloid diminishes the functioning of essential memory-related molecular 
systems within the neuron. There is a dynamic nature of specific neuronal 
transcripts that lend to the ability of the brain to retain information and it seems 
that amyloid disrupts this system in multiple ways. It is possible that as the IEG 
induction decreases, it reaches a point at which the strength of the subsequent 
memory trace is inadequate to modify the mouse’s behavior. It has already been 
shown in multiple mouse models that amyloid deposition is associated with the 
decline of cognitive function (Chen et al. 2000;Gordon et al. 2001;Westerman et 
al. ;Heikkinen et al. 2002). These data provide the first hints of a molecular basis 
for this problem. The results herein suggest potential targets for therapy and 
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prophylaxis of amyloid-associated dementias and possibly other forms of 
cognitive impairments that are to this point poorly understood at the level of gene 
expression.  
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FIGURE 1. Time course of gene expression in the hippocampus of transgenic 
mice by qRT-PCR. 
Panel “A” shows the differential expression (transgenic expression (n=7-8 
APP+PS1) relative to non-transgenic expression (n=7-8 Non-Tg; set as 100% for 
each gene) for three IEGs (Arc, Zif268 and Nur77) that were 1) unaffected at 2 
months, prior to amyloid development, 2) significantly down-regulated in 
transgenic animals by 6-months of age, and 3) further down-regulated by 18 
months. Synaptophysin remained equivalent to non-transgenic animals 
throughout their lifespan. Panel “B” shows the differential expression for a set of 
plasticity-related genes (CaMKIIα, GluR1, and Na, K ATPase αIII) that were 
unchanged at both the 2 and 6 month time points, with the exception of CaMKIIα 
at 6 months. However, by 18 months these genes were all significantly down 
regulated. Gap43 remained equivalent to non-transgenic animals throughout 
their lifespan. Panel “C” summarizes these findings by averaging the values for 
each gene into the representative category and analyzing these for significance 
by one-way ANOVA. The values represented in this figure are the mean + SEM. 
“*” indicates significant differences between APP+PS1 mice and non-transgenic 
littermates (p < 0.05). 
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FIGURE 2. Gene expression in hippocampi of APP only, PS1 only and APP+PS1 
transgenic mice at 18 months of age by qRT-PCR. 
This figure compares expression of doubly transgenic APP+PS1 mice and 
age-matched single transgenics with non-transgenic littermates. Black bars 
indicate PS1 only mice, gray bars indicate APP only mice and white bars indicate 
APP+PS1 mice. The far left panel describes the differential expression 
(transgenic expression (n=7-8 APP+PS1) relative to non-transgenic expression 
(n=7-8 Non-Tg; set as 100% for each gene) for Arc, Zif268 and Nur77. These 
genes were down-regulated in both APP only and APP+PS1 transgenic animals, 
however the PS1 only transgenics had no deficits in expression. The center 
panel reveals that the plasticity-related genes CaMKIIα, GluR1, and Na, K 
ATPase αIII were down-regulated at 18 months only in the APP+PS1 transgenic 
mice, while APP only and PS1 only expression remained equivalent to that of 
non-transgenics. The right panel demonstrates the specificity of this effect by 
showing that other synaptic genes were not influenced by genotype in any of the 
3 transgenic models. Expression values for the APP only and APP+PS1 
transgenics could also be compared statistically to determine if the differing 
levels of expression were significant between the two models. The values 
represented in this figure are the mean + SEM.  “*” indicates significant 
differences between APP+PS1 mice and non-transgenic littermates (p < 0.05). 
"†" above the bracket indicates differences (P < 0.05) in expression between 
APP+PS1 mice and APP only mice. 
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FIGURE 3. Gene expression profile in hippocampus, posterior cortex and 
caudate nucleus of APP+PS1 transgenic mice at 18 months of age by qRT-PCR. 
This figure compares gene expression in three different brain regions of 
doubly transgenic APP+PS1 mice with non-transgenic littermates. Black bars 
indicate caudate nucleus (CN), gray bars indicate posterior cortex (CX) and white 
bars indicate hippocampus (HC) in APP+PS1 mice. The far left panel describes 
the differential expression in each brain region (transgenic expression (n=7-8 
APP+PS1) relative to non-transgenic expression (n=7-8 Non-Tg; set as 100% for 
each gene) for Arc, Zif268 and Nur77. These genes were significantly down-
regulated in all three regions. The center panel reveals that the plasticity-related 
genes CaMKIIα, GluR1, and Na, K ATPase αIII were down-regulated at 18 
months only in the HC of APP+PS1 transgenic mice, with the exception of 
CaMKIIα which is significantly down-regulated in the CX. The right panel 
demonstrates the specificity of this effect by showing that other synaptic genes 
were not influenced in any of the brain regions. Expression values for the HC and 
CX could also be compared statistically to determine if the differing levels of 
expression were significant between the two regions. CN was not compared, as 
these values were even closer to non-transgenic than those of CX. The values 
represented in this figure are the mean + SEM.  “*” indicates significant 
differences between APP+PS1 brain regions and those of non-transgenic 
littermates (p < 0.05). "†" above the bracket indicates differences (P < 0.05) in 
expression between PCX and HPC of APP+PS1 mice. 
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FIGURE 4. IEG expression measured by qRT-PCR in hippocampi of APP+PS1 
transgenic mice and non-transgenic littermates following Induction by 
environmental novelty. 
This figure compares expression of IEGs between APP+PS1 mice and 
non-transgenic littermates either following induction by a 5 minute exposure to a 
novel environment with a subsequent 30 minute period in a new cage, or 
immediate euthanitazation after removal from their home environment. White 
bars indicate those mice that were euthanatized quickly to measure basal 
expression. Black bars indicate those animals that were exposed to 
environmental novelty to measure induced expression. ANOVA indicated a 
significant effect of induction for Arc (F= 38.8; P < 0.0001), Nur77 (F= 26.1; P < 
0.0001), and Zif268 (F= 27.992; P < 0.0001). There was also a significant 
interaction between genotype and induction for Arc (F= 4.4; P < 0.05) and Nur77 
(F= 4.3; P < 0.05), but not Zif268. The values represented in this figure are the 
mean + SEM.  “*” indicates a significant interaction effect between genotype and 
treatment (p < 0.05) as determined by two-way ANOVA.  
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TABLE 1. Expression of non-inducible genes in APP+PS1 mice stimulated by 
environmental novelty compared to non-transgenic littermates by qRT-PCR. 
Values indicate percent reduction in APP+PS1 mouse hippocampus RNA 
expression compared to non-transgenic littermates’ ± SEM. No induction 
occurred for these genes, therefore mice were analyzed by genotype only using 
one-way ANOVA.  “*” indicates significantly different from non-transgenic mice at 
P<0.05.  
 Gene 
Properties Marker mRNA Non-Induced 
CaMKIIα 87.3 ± 5.2* 
GluR1 83.8 ± 6.6* Plasticity-Related Genes 
Na, K ATPase αIII 83.3 ± 5.9* 
Gap43 95.6 ± 4 Non-Changing 
Synaptic 
Genes Synaptophysin 95.4 ± 5.1 
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ABSTRACT 
The pathology of Alzheimer’s disease (AD) is comprised of extracellular 
amyloid plaques, intracellular tau tangles, dystrophic neurites and 
neurodegeneration. The mechanisms by which these various pathological 
features arise are under intense investigation. Here, based on pilot gene 
expression studies, we have further analyzed the relationship between Na+/K+ 
ATPase and amyloid using the APP+PS1 transgenic mouse model. We report 
that in addition to decreased mRNA expression, there is decreased overall 
activity of the enzyme specifically in the amyloid-containing hippocampi of the 
APP+PS1 mice. In addition, dual immunolabeling reveals an absence of Na+/K+ 
ATPase protein in a circumferential zone near congophilic plaques that is 
occupied by dystrophic neurites. We also demonstrate that cerebral Na+/K+ 
ATPase activity can be directly inhibited by high concentrations of Aβ. In AD, the 
local concentration of Aβ within the immediate vicinity of plaques may inhibit 
Na+/K+ ATPase activity. Loss of ionic homeostasis may result in synaptic edema 
and the appearance of dystrophic neurites. It might also be expected that the 
electrotonic properties of processes would be modified by loss of ionic balance, 
leading to disruption of synaptic integration and, conceivably, learning and 
memory. Therapies aimed at maintaining osmotic balance by enhancing Na+/K+ 
ATPase activity in early stage AD may delay the disease’s progression. 
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INTRODUCTION 
Alzheimer’s disease (AD) has several well characterized post-mortem 
pathological markers that include both gliosis and dystrophic neurites 
surrounding extracellular amyloid plaques. In addition, intracellular tangles of 
hyper-phosphorylated tau and massive neurodegeneration are seen later in the 
disease process. Mutated forms of both amyloid precursor protein (APP) and 
presenilin 1 (PS1) leads to an increased rate of amyloid deposition and therefore 
an earlier onset of the dementia associated with AD (Selkoe, 2001). Doubly 
transgenic mice expressing these human mutants of the APP (Hsiao et al., 1996) 
and PS1 (Duff et al., 1996) genes (APP+PS1 mice; Holcomb et al., 1998) exhibit 
a tremendous amount of amyloid deposition and gliosis without the formation of 
tangles or neuron loss, and yet they still develop anterograde amnesia as they 
age, similar to what is seen in the early stages of AD (Morgan, 2003). Memory 
deficits without the loss of neurons indicate that amyloid-associated disruption of 
some step in neural processing can result in memory deficits. 
 Previously we have described decreased expression of genes critical for 
learning and memory and impaired induction of several immediate early genes 
(IEGs) in aged, memory deficient APP+PS1 mice (Dickey et al., 2003;Dickey et 
al., 2004). Increased neural activity during learning is argued to be a primary 
inducing stimulus for these IEGs (Dragunow, 1996). One possible mechanism to 
describe this phenomenon would be that amyloid is diminishing the ability of 
neurons to facilitate sufficient electrical signaling to induce changes in synaptic 
plasticity essential for memory consolidation. Here we present evidence that in 
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addition to a decreased level of Na+/K+ ATPase mRNA, the activity of this 
enzyme is significantly decreased in the APP+PS1 hippocampus but not in the 
amyloid-free cerebellum, an important finding as ouabain administration has 
been shown to impair memory consolidation (Watts and Mark, 1971; Mark and 
Watts, 1971). We decided to investigate further the interactions of Aβ and 
Na+/K+ ATPase activity to understand better the role of this enzyme in AD and 
memory dysfunction. 
 
MATERIALS AND METHODS 
Tissue Preparation 
Mice were bred in our facility and genotyped using previously described 
methods (Gordon et al., 2001). The working memory performance of the 
APP+PS1 mice used in these studies was impaired when compared to non-
transgenic littermates as published previously (Austin et al., 2003; untreated 
groups were studied here). Briefly, 17-18 month old mice were deeply 
anesthetized with pentobarbital (100 mg/kg) and perfused transcardially with 
phosphate buffered saline. Brains were removed and halved into right and left 
hemispheres. The right hemisphere was immediately dissected into regions and 
frozen on dry ice, while the left hemisphere was post-fixed in 4% para-
formaldehyde for 24 hours and subsequently processed through a cryo-
protection schedule of 10, 20 and 30% sucrose.  Frozen brains were sectioned 
horizontally on a sliding microtome at 25 µm and stored in Dulbecco’s phosphate 
buffered saline plus azide at 4° C. 
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Real time RT-PCR Analysis 
 As previously described, real time RT-PCR was used to measure 
expression levels of mouse Na+/K+ ATPase αIII (NAK3) mRNA from total RNA 
extraction of both hippocampus and cerebellum tissue (Dickey et al., 
2003;Dickey et al., 2004). 18S ribosomal RNA was used as the stably expressed 
denominator across tissue samples. The following primers for NAK3 were 
designed using the mouse sequence from the NCBI accession number 
NM_144921: Forward primer 5’ CAA GAA GAG CAA GGC CAA AG 3’ and 
reverse primer 5’ TTG TAT TTC CGG CAG ACC TC 3’. The sequences for the 
18S rRNA primers were acquired from Schmittgen and Zakrajsek (2000).  
 
Na+/K+ ATPase Activity Assay & Amyloid Preparation 
 An assay to detect specific activity of Na+/K+ ATPase by measuring the 
release of phosphate was developed using a variation of the method described 
by Ellis et al. (2000). Freshly frozen dissected hippocampi and cerebella (20-
30mg tissue weight) from APP+PS1 and non-transgenic littermates were 
homogenized using a rotor-stator homogenizer in 1 ml of cold suspension buffer 
containing 85mM NaCl, 20mM KCl, 4mM MgCl, 0.2mM EGTA and 30mM 
histidine pH 7.2. Saponin was added to the samples to a final concentration of 
20µg/ml. They were then incubated at 37°C for 15 minutes and immediately 
returned to ice. Protein concentration was measured by Bradford assay and 
concentrations were adjusted to 10mg/ml tissue weight. 
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 In a 96-well plate, 60µl of ATP buffer containing 140mM NaCl, 20mM KCl, 
3mM MgCl, 30mM histidine and 3mM ATP were added to wells. Two sets of 
samples were setup, one with ATP buffer only and the other with 100µM of the 
Na+/K+ ATPase selective inhibitor ouabain added to the ATP buffer. 
Subsequently, 10µl of protein homogenates were added to the ATP buffer ± 
ouabain, which were then mixed by pipetting and incubated at 37°C for 30 
minutes. The reaction was stopped by adding 120µl of an acid molybdate 
solution consisting of 0.5g ammonium molybdate (Sigma, St. Louis, MO) in 0.5M 
sulfuric acid. After mixing, 10µl of Fiske Subbarow Reducer (Sigma, St. Louis, 
MO) was added and wells were mixed again. The plate was allowed to incubate 
covered at room temperature for 10 minutes and then measured 
spectrophotometrically at 660nm. Specific activity was measured by taking the 
difference between samples ± ouabain and, using a standard curve of serially 
diluted 4mM phosphoric acid, converting this OD value to µmols of inorganic 
phosphate (Pi) liberated/mg protein/ hour. All reactions were performed in 
triplicate, which were then averaged to produce the single value for the sample. 
Differences between APP+PS1 and non-transgenics were analyzed for 
significance using one-way ANOVA. 
For analysis of activity inhibition by Aβ, purified active cortical Na+/K+ 
ATPase (Sigma, St. Louis, MO) was pre-incubated for 2 hours in a 37°C orbital 
shaker separately with 112.5, 225 and 450 µg/ml of Aβ 1-42 or vehicle only. 
Activity was then measured using the same activity assay as above and 
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significance was measured using one-way ANOVA comparing activity between 
vehicle treated and Aβ treated. 
 Aβ used for these studies was generated by resuspending 1mg of 
commercially available recombinant Aβ 1-42 peptide (rPeptide, Athens, GA) in 
221µl of 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Sigma, St. Louis, MO) to 
generate 45µg Aβ 1-42 films. These films were resuspended in 2µl of dry DMSO, 
followed by agitation and subsequent addition of 48µl of cold water and overnight 
incubation at 4°C. This yielded approximately a 900µg/ml suspension of Aβ. 
Quality of the peptide was confirmed using SDS-PAGE analysis. 10µl of the 
overnight preparation was mixed with 2x sample buffer (62.5mM Tris-HCl, 10% 
glycerol, 10% SDS, and 0.1% bromophenol blue), without β-mercaptoethanol or 
heat, and loaded onto a 4-20% gradient Tris-glycine gel (Bio-Rad, Hercules, CA) 
and run at 100mV for 60-90 minutes. This was followed by an overnight 
Comassie Blue stain of the gel and a prolonged destain in water the following 
day.   
 
Histology 
Immunohistochemical and immunofluorescence analyses for Na+/K+ 
ATPase α III and phosphorylated neurofilament, respectively, were performed on 
the same 25µm free-floating hippocampal sections. Sections were treated 15 
minutes with 10% methanol, 10% hydrogen peroxide and 80% PBS to block 
endogenous peroxidase activity, and then washed 3 times with PBS. Sections 
were subsequently treated with sodium borohydride for 15 minutes to reduce 
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background auto-fluorescence (Clancy and Cauller, 1998) followed by washing 
with PBS. Sections were then permeabilized for 30 minutes with 100mM lysine, 
0.2% triton x-100, 2% goat serum and 2% horse serum in PBS, and washed 3 
times with PBS.  Sections were then incubated overnight in a 1:300 dilution of 
goat F(ab’)2 anti-mouse IgG (Protos Immunoresearch, Burlingame, CA) to block 
endogenous mouse IgG. Sections were washed the following day and co-
incubated with a 1:5000 dilution of a rabbit anti-rat Na+/K+ ATPase α III IgG 
(Upstate Biotech, Lake Placid, NY) and a 1:10,000 dilution of a mouse 
monoclonal IgG1 ascites pool specific for phosphorylated forms of neurofilament 
(SMI-312; Sternberger Monoclonals, Lutherville, MD) in 2% goat serum and 2% 
horse serum in PBS. The following day, sections were washed, and then 
incubated in both a 1:3000 dilution of anti-rabbit biotinylated secondary antibody 
(Vector Labs, Burlingame, CA) and a 1:100 dilution of anti-mouse fluorescein 
conjugated secondary antibody (Vector Labs, Burlingame, CA) for 2 hours.  After 
washing, the tissue was incubated with Vectastain Elite ABC kit (Vector Labs, 
Burlingame, CA). The tissue was then washed and stained with a 
diaminobenzidine:peroxide system plus nickel enhancement (DAB/Ni2+), followed  
by final washes.  Compact amyloid plaques were visualized using Congo red 
staining after sections were slide mounted and dried (Gordon et al., 2001). 
Briefly, slides were incubated in alkaline alcoholic saturated sodium chloride  
(AASSC), followed by 0.2% Congo red in AASSC, then dehydrated and cover-
slipped with xylene-free Vectamount (Vector Labs, Burlingame, CA; other 
mounting media were tested, but only Vectamount was suited for both 
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immunohistochemistry, immunofluorescence and Congo red staining). The extent 
of nonspecific binding was assessed in the absence of primary antibodies for all 
assays.  Specificity of the Na+/K+ ATPase antibody was confirmed by reduced 
staining following a 2 hour pre-incubation of the antibody with purified cerebral 
ATPase at a 1 to 4 molecule ratio (1 antibody to 4 protein molecules). Both 
immunostains were characterized individually before the co-incubation procedure 
was implemented. 
 
Western Blot 
Brain homogenate from the activity assay above was equilibrated to 10µg 
of total protein. This homogenate, along with 1 mg of purified cerebral Na+/K+ 
ATPase, was diluted 1:1 with loading buffer containing 4% SDS and 5% β-
mercaptoethanol, heated to boiling for 5 minutes and loaded onto a 7.5% Tris-
glycine gel which was then electrophoresed at 100mV for one hour in the 
presence of SDS. The protein was subsequently transferred onto an Immobilon 
membrane (Millipore, Billerica, MA) for an hour at 100mV. The blot was rinsed 
with borate saline + 0.05% Tween-20 (BST) and blocked overnight at 4°C in 5% 
non-fat dry milk (NFDM). The following day, a 1:2000 dilution of anti-rat Na+/K+ 
ATPase αIII antibody (Upstate Biotech, Lake Placid, NY) in 0.5% NFDM+BST 
was applied to the blot for 1 hour, followed by washing and a subsequent 1 hour 
incubation with a 1:5000 dilution of  hrp-labeled anti-rat IgG (Sigma, St. Louis, 
MO) in 0.5% NFDM+BST. After washing, the blot was developed for 
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chemiluminescence using a luminol substrate kit (Santa Cruz Biotech, Santa 
Cruz, CA) and film exposure.    
 
RESULTS 
 The pathology underlying AD is vast and complex, but through the use of 
transgenic models that develop various aspects of the disease, our 
understanding of how each pathological feature contributes to the progression of 
AD can be improved. Here we have used the APP+PS1 transgenic mouse model 
to better understand how the deposition of amyloid and the subsequent 
deleterious effects of its presence are contributing to the consistent memory loss 
seen in these animals (Morgan et al., 2000;Gordon et al., 2002;Arendash et al., 
2001;Austin et al., 2003).  Specifically, we have found that Na+/K+ ATPase, a 
protein critical for not only brain function, but survival, is adversely affected by the 
presence of amyloid and this interaction may be driving a major pathological 
event in the progression of amyloid-associated dementia.  
Initial quantitative real-time PCR (qRT-PCR) investigations revealed that 
the expression of the Na+/K+ ATPase brain-specific catalytic subunit (α III) 
mRNA is significantly (25-30%) decreased in the amyloid rich hippocampus of 
memory deficient APP+PS1 mice when compared to both the non-transgenic 
littermate hippocampus and the amyloid-free cerebellum of these same doubly 
transgenic mice (Figure 1). This supported the notion that amyloid is specifically 
altering expression of genes, thereby contributing the inability of these mice to 
perform well in a radial arm water maze task.  To determine whether the Na+/K+ 
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ATPase protein itself was being modified in agreement with the reduced mRNA 
levels, we initially performed Western blot analysis; however, we found that this 
method was not sufficiently sensitive to detect the modest reduction in 
expression (data not shown). We turned to a more quantitative approach, using a 
colorimetric assay to measure activity of the enzyme. Using ouabain as a 
selective inhibitor for Na+/K+ ATPase, we demonstrated that the enzymatic 
activity as measured by µmols of Pi liberated/ mg of protein/ hour was 
significantly reduced by ~25% in the hippocampi of aged, memory-deficient 
APP+PS1 mice compared with non-transgenic littermates (Figure 2). These 
values are consistent with those found 3 decades ago by Stefanovic et al. (1974). 
Upon analysis of the cerebellum of these mice, we showed that the specific 
enzyme activity in APP+PS1 transgenics remained equivalent to that in non-
transgenic littermates; however the overall activity of Na+/K+ ATPase in this 
region was only one fifth of that in the hippocampus (Figure 2).  
The specificity of the Na+/K+ ATPase α subunit antibody used for 
immunochemistry was determined by several means. Figure 3 demonstrates that 
following a pre-incubation of the antibody with purified Na+/K+ ATPase protein, 
staining with DAB+Ni2+ was dramatically reduced (Figure 3B) compared with 
normal staining (Figure 3A; the bright red spots are amyloid plaques stained with 
Congo red dye). Western blot analysis of the purified enzyme revealed two major 
bands the largest corresponding to the 140kD whole Na+/K+ ATPase enzyme 
consisting of both the α and β subunits and the smaller 110kD band 
corresponding specifically to the dissociated α subunit only (Figure 3C). The 
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Western banding pattern of mouse hippocampal homogenate (signified by the 
“H” above the right lane) was virtually identical with that of the purified Na+/K+ 
ATPase (signified by the “P” above the left lane; Figure 3C). These data provided 
sufficient evidence of the reliability of antibody specificity to continue with more 
comprehensive anatomical analyses of the APP+PS1 cerebral Na+/K+ ATPase 
distribution.      
Immunohistochemical staining with DAB+Ni2+ of cerebral sections from 
non-transgenic and APP+PS1 mice for the Na+/K+ ATPase α III subunit revealed 
specific membrane-associated staining as evidenced by the high magnification 
images in Figure 4 of CA3 pyramidal cell bodies (Figure 4A) and cell bodies of 
the insular cortex (Figure 4B) with reticular staining in the neuropil. Lower power 
images of the hippocampus in non-transgenic mice (Figure 4C) demonstrate an 
absence of staining along the granular layer of the blades of the dentate gyrus. 
Additionally, staining is less intense within the hilus and along the mossy fiber 
projections to CA3, demonstrating a lower expression of this protein subunit in 
the inner molecular layer of CA3, but not in the pyramidal layer (Figure 4A).  
White matter lacked staining consistent with the need for high Na+/K+ 
ATPase activity only at the nodes of Ranvier in myelinated tracts. Cortical 
staining (Figure 4D) revealed a fairly uniform pattern, with the exclusion of white 
matter. There appears to be slightly less intense staining in cortical layers 1 and 
2. The glaring difference in Na+/K+ ATPase staining between non-transgenic and 
APP+PS1 forebrain areas is the absence of staining where amyloid plaques are 
presumably present in the APP+PS1 mice (Figure 4E & F). Subsequent Congo 
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red staining of these amyloid plaques confirmed that the absence of Na+/K+ 
ATPase staining was not only seen in the center of the plaque, but also in a 
penumbral zone immediately surrounding the congophilic plaque, resulting in a 
“halo” (Figure 4G & H).  Higher power magnification clearly demonstrated the 
lack of Na+/K+ ATPase staining surrounding the congophilic plaques (Figure 5A; 
100x: Figure 5B; 400x). 
These findings led us to postulate that the osmotic imbalance brought on 
by an absence of Na+/K+ ATPase may result in the neuritic dystrophia 
surrounding plaques, a pathological feature consistently seen in APP+PS1 mice. 
We designed a dual immunostain utilizing immunohistochemical methods for 
Na+/K+ ATPase and immunofluorescence methods for phosphorylated 
neurofilament, a dystrophic neurite marker we evaluated earlier (Gordon et al., 
2002). Figure 5B is representative of our findings for Na+/K+ ATPase with Congo 
red and Figure 5C is likewise representative of our findings for phosphorylated 
neurofilament (dystrophic neurites) on the same plaque. Using this assay, we 
were able to demonstrate that the dystrophic neurites were almost exclusively 
present within the zone surrounding the congophilic plaque that lacked Na+/K+ 
ATPase staining, as represented by an overlay of the fluorescent neurites from 
Figure 5C onto the bright field image of  Na+/K+ ATPase and Congo red staining 
from Figure 5B (Figure 5D).  
Finally, to determine whether amyloid could inactivate Na+/K+ ATPase 
activity, we measured the activity of purified cerebral Na+/K+ ATPase after 
exposure to various concentrations of Aβ 1-42 peptide. Figure 6A shows that the 
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amyloid preparation contained peptide forms corresponding to ~15, ~11, and 
~4kD (right lane), when compared to the molecular weight standards in the left 
lane. Figure 6B demonstrates that increasing concentrations of Aß dose-
dependently reduced Na+/K+ ATPase activity. There were significant reductions 
in Na+/K+ ATPase activity at the lower concentrations of 112 and 225 µg/ml 
compared to vehicle, but maximal reductions were at the highest concentration of 
amyloid (450µg/ml).  
 
DISCUSSION  
Over the past 6 years, our group has characterized various aspects of the 
APP+PS1 transgenic mice including their pathology, behavior, and gene 
expression. With age, these mice progressively develop more amyloid plaques 
surrounded by dystrophic neurites, activated microglia and astrocytes (Gordon et 
al., 2002). With increasing amyloid burden, aged animals consistently develop 
memory deficits in the radial arm water maze (RAWM; Holcomb et al., 
1999;Arendash et al., 2001;Gordon et al., 2001). We have also demonstrated 
that several genes critical for synaptic plasticity and memory consolidation are 
down regulated in these mice in regions accumulating amyloid (Dickey et al., 
2003) and the induction of a subset of immediate-early genes is impaired when 
the transgenic mice are introduced to a novel environment (Dickey et al., 2004).  
Here, we have shown that Na+/K+ ATPase has decreased mRNA 
expression and enzyme activity in the amyloid containing hippocampus of 
APP+PS1 transgenic mice. We have also demonstrated by immunohistology that 
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Na+/K+ ATPase protein expression is reduced in the immediate vicinity of 
congophilic plaques, a zone where dystrophic neurites are most prevalent, 
suggesting that disrupted ionic homeostasis may contribute to their formation. 
Additionally, high concentrations of Aβ 1-42 directly inhibit the activity of Na+/K+ 
ATPase. This suggests that in the area surrounding amyloid plaques, where the 
local Aβ concentration is likely high, Na+/K+ ATPase activity is inhibited, 
precipitating edema in neurites close to the plaques.        
 From previous gene expression studies, we found that the mRNA for the 
Na+/K+ ATPase αIII subunit was significantly down-regulated in the hippocampi 
of APP+PS1 mice compared to non-transgenic littermates and to the amyloid-
free cerebella (Dickey et al., 2003). These reductions were also demonstrated in 
human Alzheimer’s disease samples, consistent with data from previous 
investigations (Chauhan et al., 1997; Dickey et al., 2003). Here, we have 
replicated these findings in a separate cohort of aged APP+PS1 mice, 
demonstrating a consistent deficiency (Figure 1). Two major advantages of the 
qRT-PCR method are sensitivity and robustness, as discrete changes in 
expression can be measured and sample size can be increased to allow for more 
reliable statistical analyses, respectively. One problem is that current 
conventional methods used to measure protein expression lack the same 
sensitivity now available for RNA analyses, and therefore may not discern similar 
phenomena at the protein level. Using Western blot analysis, we were able to 
see slight differences in Na+/K+ ATPase protein level in transgenic mice; 
however this approach lacked statistical significance and was less than 
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convincing to our eyes (a representative blot is shown in Figure 3C). Using a 
sensitive colorimetric assay to measure activity of Na+/K+ ATPase developed by 
Ellis et al. (2000), we were able to demonstrate that in the APP+PS1 
hippocampus, the activity of ouabain-sensitive ATPase was significantly impaired 
(Figure 2) while Na+/K+ ATPase activity in the amyloid-free cerebellum remained 
unperturbed with respect to genotype. Cerebellar activity was substantially lower 
than that seen in the non-transgenic hippocampal tissue, perhaps indicative of 
the abundant white matter found in this region, where Na+/K+ ATPase would 
predominantly be located at the nodes of Ranvier. These data demonstrate that 
the function of Na+/K+ ATPase is perturbed in a brain region that contains high 
overall concentrations of Aβ. Previous investigations have shown that in cultured 
neurons, Na+/K+ ATPase activity can be blocked directly by various Aβ peptide 
fragments (Mark et al., 1995) and other studies have shown that Na+/K+ ATPase 
protein levels are decreased in AD tissue but not in normal aged tissue (Harik et 
al., 1989;Liguri et al., 1990) But, this is the first time that reduced activity has 
been demonstrated in homogenates from an animal model for amyloid deposition 
indicating that in vitro effects of Aβ retain relevance in vivo. It remains uncertain if 
the Aβ in the homogenate is directly inhibiting the enzyme in vitro, as the 
homogenate is diluted 20 fold in the assay. However, even if this reduced activity 
results from homogenate-derived Aβ inhibition in vitro, it clearly indicates there is 
sufficient Aβ in vivo to block Na+/K+ ATPase activity. 
 We then immunostained APP+PS1 mouse sections for Na+/K+ ATPase to 
better understand where the reductions in enzyme level were occurring. Initial 
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examination of hippocampal staining revealed that in both the non-transgenic 
and APP+PS1 mice, Na+/K+ ATPase staining was found to be membrane 
specific (Figures 3A & B). Analysis of staining in both APP+PS1 and non-
transgenic tissue also revealed reductions in Na+/K+ ATPase along the mossy 
fiber pathway from dentate gyrus to  CA3 and in the hilus and slight reductions in 
layers 1 and 2 of the cortex  (Figure 4A-F).  Of particular interest, in areas where 
congophilic plaque staining was apparent, Na+/K+ ATPase staining was absent, 
and more specifically, there appeared to be no or little Na+/K+ ATPase staining 
in a penumbral zone surrounding the plaques stained with Congo red (Figures 
4E-H and 5A-B). From previous studies, we knew that dystrophic neurites could 
be visualized in the APP+PS1 mice directly adjacent to congophilic amyloid 
plaques (Gordon et al., 2002) and the finding of reduced Na+/K+ ATPase 
staining in this same area suggests that dysregulation of the enzyme may in 
some way be linked to the disruption of neurite integrity.  
Subsequently, we stained sections for Na+/K+ ATPase and dystrophic 
neurites together, along with amyloid plaques using Congo red. Because of the 
ubiquitous distribution of both Na+/K+ ATPase and phosphorylated neurofilament 
(used to label dystrophic neurites), we found empirically that staining the ATPase 
immunohistochemically and the dystrophic neurites with a fluorescein labeled 
secondary antibody was the most effective way to see both markers on the same 
section along with the Congo red stained plaques.  Imaging of these sections did 
reveal that dystrophic neurites are in the circumferential area surrounding the 
congophilic amyloid plaques where Na+/K+ ATPase staining is absent (Figure 
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5D). One possible explanation for this would be that amyloid binding to the 
Na+/K+ ATPase and inhibiting its activity would cause the neurites to begin 
swelling, resulting in dysregulation of neuronal signaling. Another possible 
mechanism for the reductions in Na+/K+ ATPase would be that interactions of 
amyloid with surface proteins, such as integrins (Sabo et al., 1995;Goodwin et 
al., 1997) and focal adhesion proteins (Williamson et al., 2002) lead to activated 
signal transduction cascades that mediate tyrosine phosphorylation (Grace and 
Busciglio, 2003) thereby promoting the removal of ATPase from the neuronal 
membrane and its subsequent down-regulation. A recent study suggests that the 
tyrosine kinase, Lyn, can phosphorylate Na+/K+ ATPase resulting in its removal 
from the membrane (Bozulic et al., 2004). When taken together, these data 
suggest that either direct inhibition of Na+/K+ ATPase by amyloid or its removal 
due to amyloid-mediated activation of a signaling cascade, could result in the 
formation of dystrophic neurites due to osmotic and ionic imbalances.              
  A final investigation analyzed the effects of amyloid peptide on the activity 
of a purified cerebral preparation of active Na+/K+ ATPase. Amyloid has been 
shown to bind various cell surface proteins (Mark et al., 1995;Dineley et al., 
2001;Verdier and Penke, 2004) and induce neuro-toxicity (Caughey and 
Lansbury, 2003;Stine, Jr. et al., 2003;Gong et al., 2003). To determine the effect 
of Aβ 1-42 on Na+/K+ ATPase activity, we pre-incubated purified Na+/K+ 
ATPase with varying concentrations of amyloid then colorimetrically measured its 
activity. Although amyloid did suppress activity at 112 µg/ml (~10µM) and 225 
µg/ml (~50µM), it was the highest concentration (450µg/ml or ~100µM) that 
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precipitated the largest reduction in activity compared to vehicle, nearly rendering 
it completely inactive (Figure 6B). This suggests that the Aβ 1-42 peptide can 
directly binding to the Na+/K+ ATPase and affecting its activity. Mark et al. 
suggests that the 25-35 amino acid region of the Aβ peptide induces oxidative 
stress thereby impairing Na+/K+ ATPase activity (Mark et al., 1995), and the 
findings presented herein strengthen the argument for the role of amyloid in 
Na+/K+ ATPase dysregulation. Additionally, the presence of short 11 and 15 kD 
polymers of amyloid in the DMSO/water preparation suggests that these might 
be what is driving this reduced activity.   
These data indicate that reduced activity in Na+/K+ ATPase may be 
elicited by high concentrations of Aβ, which may then lead to local neuritic edema 
and the appearance of dystrophic neurites in APP+PS1 mice. One area in the AD 
brain that might harbor such a high concentration of Aβ as needed to suppress 
the activity of Na+/K+ ATPase would be the microdomain near and immediately 
around the plaques. This is the area demonstrated to have reduced 
immunostaining for Na+/K+ ATPase. A previous study has suggested that when 
Na+/K+ ATPase activity is specifically inhibited by ouabain, mice are unable to 
consolidate new memories  (Watts and Mark, 1971) and in addition cells exposed 
to ouabain have reduced Na+/K+ ATPase αIII subunit mRNA expression (Huang 
et al., 1997), confirming our findings that direct inhibition of Na+/K+ ATPase 
activity can result in reduced mRNA expression, possibly through a yet 
unidentified signaling cascade. These data suggest that drugs targeted at 
activating Na+/K+ ATPase and maintaining ionic balance in these neurons may 
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benefit Alzheimer’s patients by delaying both the onset of neuritic dystrophia and 
memory dysfunction.    
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FIGURE 1. Expression of Na+/K+ ATPase mRNA in APP+PS1 mice by qRT-
PCR. 
  This figure shows APP+PS1 transgenic mouse expression (n=7-8 
APP+PS1, open bars) as a percentage of the average of non-transgenic 
expression (n=7-8 Non-Tg, solid bars) for the Na+/K+ ATPase αIII subunit in the 
hippocampus and the cerebellum. In 18 month old APP+PS1 mice, the amyloid 
free cerebellum maintains expression equivalent to that of non-transgenic mice. 
However, hippocampal expression of Na+/K+ ATPase is significantly decreased 
in APP+PS1 mice compared with age matched littermates, indicating that the 
amyloid contained within this region may be contributing to the decrease in 
mRNA expression. The values represented in this figure are the mean + SEM. * 
indicates significant differences between APP+PS1 mice and non-transgenic 
littermates (p < 0.05) when measured by one-way ANOVA. † indicates 
differences (p < 0.05) in expression between hippocampus and cerebellum. 
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FIGURE 2. Activity of the Na+/K+ ATPase enzyme in APP+PS1 mice 
Activity of ouabain-sensitive ATPase was assayed colorimetrically in 
APP+PS1 mice tissue (n = 8, open bars) and non-transgenic littermate tissue (n 
= 8, solid bars) and is presented here as µmols of phosphate liberated by 
Na+/K+ ATPase per mg of protein in one hour. Both amyloid-free cerebellar 
tissue and amyloid containing hippocampal tissue were analyzed. There was no 
decrease in APP+PS1 cerebellar Na+/K+ ATPase activity compared to non-
transgenic mice. However, in the amyloid-containing hippocampus, there was a 
significant decrease in the activity of the enzyme. Cerebellar activity was only 
20% of that seen in non-transgenic hippocampus. The free-phosphate/molybdate 
complex was measured at 660nm following a 30 minute incubation. Specific 
activity was calculated as the difference between samples ± ouabain. A 
phosphoric acid standard curve was used to calculate the molar concentration of 
phosphate liberated by Na+/K+ ATPase/mg total protein/hour. The values 
represented in this figure are the mean + SEM. * indicates significant differences 
between APP+PS1 mice and non-transgenic littermates (p < 0.05) when 
measured by one-way ANOVA. 
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FIGURE 3. Verification of Na+/K+ ATPase αIII antibody specificity by 
immunohistochemistry following pre-incubation with purified protein and Western 
blotting.  
Horizontal sections were immunostained for Na+/K+ ATPase αIII with 
(Panel B) and without (Panel A) pre-incubation with 70 µunits of purified enzyme 
followed by DAB with nickel intensification and Congo red staining. The pre-
incubation significantly decreased staining, confirming antibody specificity. Panel 
C is a representative western blot for Na+/K+ ATPase αIII using both purified 
Na+/K+ ATPase (“P” lane) and hippocampal homogenate (“H” lane). Both lanes 
have two predominant bands at 140 and 110kD, corresponding to the whole 
enzyme and the α subunit, respectively, as indicated by the arrows. Scale bar for 
panels A and B = 50µm.   
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FIGURE 4. Hippocampal and cortical immunohistochemistry for Na+/K+ ATPase 
in APP+PS1 mice and non-transgenic littermates.  
Twenty five µm horizontal hippocampal and cortical sections were 
immunostained for Na+/K+ ATPase αIII followed by DAB with Ni2+ 
intensification. Left panels are hippocampus, right panels are cortical sections. 
High power magnification (Panels A & B; Scale bar = 8.33µm) revealed 
membrane-specific staining of neuronal cell bodies for Na+/K+ ATPase in the 
insular cortex (Panel B) and CA3 of the hippocampus with less intense staining 
of the mossy fiber pathway (Panel A). Hippocampal staining of non-transgenic 
mice showed a ubiquitous distribution of Na+/K+ ATPase throughout the gray 
matter, while less staining was apparent along the pyramidal layer of Ammon’s 
horn, the hilus and the granular layer of the dentate gyrus (Panel C). Cortical 
staining was also substantial with slight faintness in layers 1 and 2 (Panel D). 
White matter in both structures remained unstained. A similar staining pattern 
was observed in the APP+PS1 mice with the exception of large non-stained 
holes in the gray matter, presumably where amyloid plaques are located (Panels 
E & F). Immunostaining followed by Congo red histochemistry confirmed that the 
Na+/K+ ATPase staining was absent not only immediately where plaques are 
located, but also in a zone surrounding the plaque (Panels G & H). Scale bar for 
panels C-H = 120µm. 
 
 123
 124
FIGURE 5. Dual Immunostaining of Na+/K+ ATPase αIII and dystrophic neurites.  
Horizontal sections were immunostained for Na+/K+ ATPase using DAB 
with nickel intensification followed by Congo red staining for Aβ plaques after 
which a discernable circumferential void in ATPase staining surrounding the 
plaque was observed (Panel A 100x magnification; Panel B 400x magnification). 
Immunofluorescent staining of dystrophic neurites using the anti-phosphorylated 
neurofilament antibody SMI-312 followed by Congo red staining demonstrate a 
close relationship between amyloid plaques and dystrophic neurites (Panel C; 
Congo red yellow fluorescence was digitally suppressed to more clearly reveal 
the green-stained neurites). This double immunostaining procedure is shown as 
a digital overlay of the fluorescein-labeled dystrophic neurite image onto the 
bright field peroxidase-labeled Na+/K+ ATPase + Congo red image in panel D 
which demonstrates that dystrophic neurites are present predominantly in the 
zone devoid of Na+/K+ ATPase staining surrounding the congophilic plaques (C). 
Scale bar for Panel A = 50µm; scale bar for Panels B-D = 16.67µm.  
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FIGURE 6. Amyloid-beta 1-42 inhibits Na+/K+ ATPase activity at high 
concentrations.  
SDS-PAGE analysis followed by comassie blue staining revealed; 15 kD 
tetramers, 11kD trimers and 4kD monomers of Aß were present in the 
DMSO/water suspension (Panel A; left). Purified cerebral Na+/K+ ATPase was 
pre-incubated with three concentrations of the Aβ 1-42 suspension. Panel B 
describes the effects of Aβ on Na+/K+ ATPase activity as a percentage of the 
vehicle. The activity measured in the presence of each concentration of Aβ 1-42 
is indicated by the diamond symbol connected by a line. These findings 
demonstrate significant effects of all three concentrations of Aβ on activity, with 
75% ablation of activity at the highest concentration of 450µg/ml. The assay was 
measured spectrophotometrically at 660nm following a 2 hour pre-incubation with 
the Aβ preparations and a subsequent 30 minute reaction time. Values are 
presented here as a percentage of the activity of purified Na+/K+ ATPase 
incubated vehicle. The effect of the 2 hour pre-incubation on activity is negligible 
and indicated by the 0 µg/ml concentration. A phosphoric acid standard curve 
was used to calculate the molar concentration of phosphate liberated by Na+/K+ 
ATPase. The values represented in this figure are the mean + SEM. * (p < 0.05) 
and *** (p < 0.001) indicates significant differences between vehicle + Aβ and 
vehicle alone when measured by one-way ANOVA.  
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CONCLUSIONS 
 
Since the creation of the first transgenic mouse in 1982 by Palmiter, Chen 
and Brinster (Palmiter et al., 1982) and the subsequent use of embryonic stem 
cells to knockout genes in mice (Bradley et al., 1984), the ability to alter 
molecular expression has lead to many ground breaking discoveries in medical 
sciences. Through the use of transgenic and knockout mice, scientists have been 
able to identify the function of many human genes as well as the causes for a 
host of diseases plaguing mankind. Over the past 2 decades, many 
manipulations of these two systems have been reported allowing for expression 
of multiple genes in a single animal or the ability to induce these systems with a 
dietary supplement (Mortensen, 1993;Saam and Gordon, 1999;Shockett et al., 
1995;Bockamp et al., 2002).  
Alzheimer’s disease (AD) relies heavily on these technologies as the 
pathology associated with AD is an effect of the gradual accumulation of 
abnormal proteins in the brains of patients that eventually leads to the clinical 
manifestation of severe cognitive damage. Only a model that can duplicate this 
slow deleterious progression of pathology can be used to develop treatments for 
AD. Pathological indicators for AD include forebrain amyloid deposition resulting 
in extra-cellular plaques of β-pleated sheets and intracellular accumulation of 
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hyperphosphorylated tau filaments. A proper model for AD would also realize 
severe neuron loss and glial activation, as well as dystrophic neurites. But 
perhaps the most important feature for a model of AD to have is the inability to 
consolidate newly acquired information into lasting memories.  
Mutant forms of the human APP and PS1 genes, which have been linked 
to a more aggressive form of AD pathological progression, were used to 
generate transgenic mice. Singly transgenic APP mice were demonstrated to 
develop amyloid pathology and glial activation (Hsiao et al., 1996), while singly 
transgenic PS1 mice lacked any significant plaque pathology (Duff et al., 1996); 
however, neither model developed consistent memory deficits. These mice were 
then crossed to breed viable doubly transgenic progeny (Holcomb et al., 1998). 
The over-expression of the two transgenes led to an enhanced forebrain amyloid 
pathology and glial activation. In addition, these mice developed cognitive deficits 
that were correlated with amyloid deposition (Holcomb et al., 1999). Since that 
time, the APP+PS1 doubly transgenic mouse has provided a good model for 
therapeutic development against amyloid-associated dementias. Over the past 6 
years, our group has thoroughly characterized the pathology and behavior of 
these mice, and more recently we have begun to analyze the molecular changes 
in the APP+PS1 brain that may present other therapeutic targets for future 
benefit to AD sufferers.  
Here we present evidence describing altered gene expression in the 
APP+PS1 mice compared to non-transgenic littermates. Initial microarray 
analysis revealed that only 5 genes were down-regulated in the amyloid-
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containing forebrain of the APP+PS1 mice, whereas the amyloid-free areas 
lacked any significant down-regulation; Dickey et al., 2003). These 5 genes have 
been linked to synaptic plasticity and memory function, demonstrating their 
potentially critical role in the memory deficits of APP+PS1 mice. Additionally, 
expression of genes associated with inflammation and the acute phase reaction 
were up-regulated selectively in the amyloid-containing regions (Paper I; Table 2) 
while other genes, such as APP, were upregulated in both amyloid-containing 
and amyloid free regions compared to non-transgenic mice due to transgene 
over-expression (Paper I; Table 3).  
Using quantitative real time PCR (qRT-PCR), we were able to confirm 
most of the microarray results and add several others genes in the same 
categories as those found by the microarray (Paper I; Figure 1). One important 
feature of these data was the finding that multiple genes also associated with 
synaptic plasticity and mnemonic processes, such as Gap43, Rheb and several 
synaptic vesicle related markers, were not down-regulated in the amyloid-
containing region of APP+PS1 mice, suggesting that specific mechanisms are 
being interfered with in the APP+PS1 forebrain in response to the presence of 
amyloid. As of this writing, we have found a total of 11 genes that are down-
regulated in the amyloid containing hippocampi of 17-18 month old APP+PS1 
mice, and each of these is involved in synaptic plasticity to some degree. Of 
these 11 genes, 6 belong to the inducible immediate-early gene category while 
the other 5 are more stably expressed, but are still linked to lasting changes in 
synaptic morphology and function (Table 1). LTP- or LTD-induced synaptic 
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plasticity and the resultant gene expression have been shown to be essential for 
the long-term storage of memories in the cortex (for review see Steward, 2002 
and Lynch, 2004). These findings emphasize that the amyloid-associated 
disruption of synaptic plasticity-related mRNA expression in the APP+PS1 mice 
may be responsible for their inability to consolidate memories.  
 We also analyzed expression of these genes in both AD and non-
diseased human tissue which revealed that the amyloid-containing region had 
decreased expression of all mRNAs analyzed, while the amyloid-free tissue 
maintained normal expression (Paper I; Figure 2).  We attributed this non-specific 
loss of all mRNAs to the neurodegeneration seen with AD which is absent in the 
APP+PS1 mice. Together, these findings demonstrate that in amyloid-containing 
brain regions of memory-deficient APP+PS1 mice, there is a selective reduction 
of mRNAs associated with learning and memory, and that this impaired 
expression may be contributing to their memory dysfunction.  
To further analyze the dynamics of these reductions in mRNA expression, 
we examined tissue from APP+PS1 mice at three time points. Due to the 
expense associated with qRT-PCR, we chose three representative genes from 
both the IEG (Arc, Zif268 and Nur77) and other plasticity-related (CaMKIIα, 
AMPA1 and Na+/K+ ATPase αIII) categories, as well as two non-changing genes 
(synaptophysin and Gap43). Mice at 2 months of age lacked any reductions in 
expression of the genes we analyzed, a significant finding because it ensured 
that the reductions seen in the older mice were not due simply to APP and PS1 
over-expression,  but rather the pathological accumulation of amyloid elicited by 
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their expression (Paper II; Figure 1). Another interesting outcome of this time 
course analysis was that at 6 months, an age when fibrillar amyloid plaques are 
just beginning to appear, the IEGs were already significantly down-regulated, 
while the other plasticity-related genes had not yet demonstrated significant 
reductions (Paper II; Figure 1); however, by 18-months, when memory deficits 
and high amyloid burden are consistently detectable (Gordon et al., 2002;Gordon 
et al., 2001), both sets of genes were down-regulated (Paper II; Figure 1), 
suggesting that amyloid must be present at a sufficiently high concentration to 
block expression of both IEG and other plasticity-related mRNAs to initiate 
cognitive decline.  
Additional evidence for the enhanced sensitivity of IEG expression to 
lower amounts of Aβ was found when we analyzed APP and PS1 singly 
transgenic mice. The expression of IEGs was significantly decreased in APP only 
mice whereas the other plasticity related genes were not down-regulated, a 
similar phenomenon to that seen in the 6-month old APP+PS1 mice (Paper II; 
Figure 2). Interestingly, 18-month old APP singly transgenic mice and 6-month 
old doubly transgenic mice have a very similar amyloid load and both lack 
detectable memory deficits. The amyloid-free PS1 singly transgenic mice did not 
exhibit any significant loss in expression of the genes we analyzed (Paper II; 
Figure 2).  This emphasizes the significance of the massive amyloid burden 
found in aged APP+PS1 mice and the necessity for the down-regulation of not 
just the IEGs, but also the other plasticity related genes for memory deficits to 
occur.  
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Previously, we described that gene expression in the amyloid-free 
cerebellum remained consistent with non-transgenic littermates, demonstrating 
specificity for the down-regulated genes (Paper I; Figure 1). Subsequent 
expression analyses of the posterior cortex from 18-month old APP+PS1 mice, a 
region with a less concentrated amount of amyloid, and the caudate nucleus 
(striatum), which lacks any formation of plaques but has a high level of diffuse 
amyloid load, revealed once again that IEG expression is dysregulated by the 
presence of lower plaque load than the other plasticity-related genes. IEG 
expression was inhibited in all three regions analyzed, while the other plasticity-
related genes were only down-regulated in the hippocampus (Paper II; Figure 3). 
The down-regulation of IEG expression in the striatum is of particular interest due 
to the lack of plaque formation, but high soluble Aβ load. This perhaps provides 
the greatest evidence that amyloid itself is facilitating this disruption in some way.  
Together, the time course, genotype and anatomical analyses of 
expression provide thorough evidence that amyloid is causing the down-
regulation of IEG expression, but it is only when plaque formation is dramatically 
increased that the other plasticity-related genes are down-regulated and 
detectable memory function is disrupted. One possible reason for the apparent 
necessity of both sets of genes to be down-regulated for memory deficits to occur 
could be due to the lack of sensitivity of current behavioral trials. It could be that 
memory is just beginning to fail at the time when IEG expression is first down-
regulated. Recent reports have described impaired cognitive function when IEG 
expression is dramatically knocked down or ablated entirely (Guzowski et al., 
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2000;Bozon et al., 2003), but current methods to detect discreet changes 
associated with marginally down-regulated expression, as is the case of the 
APP+PS1 mice, may not yet be sufficiently discriminating.  
The issue of the molecular mechanisms behind the amyloid-associated 
memory loss presents a unique challenge because of the slow development of 
pathology.  Initially, we decided to address the issue of whether the induction of 
IEG expression or the low-level basal expression was impaired in the APP+PS1 
mice. This was critical because these genes are massively up-regulated following 
transcriptional induction, at which point they are capable of eliciting their most 
robust effects. Following induction, IEG expression transiently returns to near 
undetectable levels within 24 hours. Previously, to control for exactly this 
possibility, each mouse was transported from the vivarium to the laboratory and 
set aside for 30 minutes, assuming that the environmental change would be 
sufficient to induce IEG expression.  
To test if induction was in fact being sufficiently facilitated by a simple 
environmental change, we introduced one of two cohorts of mice (each cohort 
consisted of 7-8 APP+PS1 mice and 7-8 non-transgenic littermates) to a novel 
environment for 5 minutes and then returned them to a new cage for 30 minutes 
prior to sacrifice. The other cohort was swiftly removed from their home cage and 
immediately anesthetized. We designated the former as “induced” and the latter 
as “basal”. Quantitative RT-PCR of the hippocampi of these mice revealed that 
both APP+PS1 mice and non-transgenic littermates experienced significant 
induction of the IEGs Arc, Nur77 and Zif268, however the induction of Arc and 
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Nur77 in the APP+PS1 was significantly impaired compared to the non-
transgenic mice (Paper II; Figure 4). Additionally, the expression of the basal 
animals was the same for both transgenic and non-transgenic. This was an 
essential piece of evidence, as it ensured that our previous data were measuring 
functional expression of the IEGs. Zif268 induction was not significantly impaired 
in this paradigm, a finding not unexpected as the half-life of Zif268 message is 
longer than most IEGs, making it more difficult to analyze based on a single 
behavioral event. But, similar to the other 2 genes, the basal expression 
remained the same for both APP+PS1 and non-transgenic mice, further 
validating the method of induction used in our previous studies.    
   There are several possible arguments as to why IEG expression is 
decreased, including that amyloid may be binding very specifically to a cell 
surface protein, inhibiting a signaling cascade essential for IEG activation. The 
MAPK signaling cascade, specifically ERK, and CREB have both been 
implicated in the transcriptional initiation of IEG expression (Sgambato et al., 
1998;Ying et al., 2002;Murphy et al., 2004). Particularly, activation of the NMDA 
receptor has been shown to elicit expression of several IEGs, and this activation 
requires the MAPK cascade (Walker and Carlock, 1993;Cammarota et al., 2000; 
Sato et al., 2001). Amyloid and its various peptide fragments have been shown to 
inhibit LTP and facilitate LTD in an NMDA receptor-dependent manner (Kim et 
al., 2001). Therefore it is possible that amyloid is disrupting LTP via a specific 
interaction with the NMDAR, which in turn prevents sufficient stimulation to 
induce IEG expression. To further postulate, the reduced expression of the NR2B 
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subunit in the APP+PS1 mice at a point when amyloid-burden is high may 
suggest a negative feedback mechanism for the LTP system, in which perpetual 
ligand binding of the NMDAR eventually results in its decreased mRNA 
expression, similar to that seen with thyroid hormone receptor systems 
(Guissouma et al., 2000). However, these putative explanations are in conflict 
with the fact that the clinical use of low concentrations of the NMDAR antagonist, 
memantine (for review see Danysz and Parsons, 2003) is beneficial for the 
treatment of AD. Perhaps the clinical manifestation of AD is due in part to an 
over-activation of brain circuitry, in essence drowning out the fine-tuned signaling 
required for mnemonic function, a situation that may be attenuated by mild 
inhibition of the NMDAR.   
Another possible mechanism that may be altered due to 
agonist/antagonist relationships of amyloid with various receptors, is calcium 
signaling pathways. Evidence for amyloid binding to both nicotinic and 
muscarinic cholinergic receptors has been reported (Dineley et al., 2002;Kelly et 
al., 1996), both of which are involved in Ca2+ signaling, either by increasing its 
conductance into the cell or by releasing intracellular stores, respectively. We 
have demonstrated that the expression of the catalytic subunit of 
Ca2+/calmodulin-dependent kinase (CaMKIIα) is down-regulated in APP+PS1 
transgenic mice, and has significantly reduced expression in the presence of 
lower levels of amyloid, unlike the other plasticity-related genes, AMPA1 and 
Na+/K+ ATPase (Paper II; Figures 1 and 3), although not to the same extent as 
the IEGs. This suggests that calcium signaling may be disrupted in the presence 
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of low amyloid burden and this may be precipitating the decrease in IEG 
expression. As calcium signals are shorter-lived than other cascade messengers, 
they present good candidates for initiators of the transcription of the extremely 
transient IEGs (Greenberg et al., 1992;van Haasteren et al., 1999). Conversely, 
intracellular calcium release was found to be facilitated by an AD-linked mutated 
form of PS1 (Stutzmann et al., 2004). As these findings suggested, AD-linked 
mutations in PS1 may not only result in the over-production of Aß ,but also of the 
APP intracellular domain (AICD), which is the fragment thought to stimulate the 
activation of IP3 receptors on the endoplasmic reticulum (Leissring et al., 2002). 
This increased intracellular calcium release was demonstrated to activate Ca2+-
sensitive K+ channels on the cell surface, resulting in a hyperpolarization. This 
may explain another mechanism by which calcium is impeding normal neuronal 
function and decreasing signal transmission. 
In addition to amyloid pathology, APP+PS1 mice develop chronic focal 
inflammation surrounding fibrillar plaques. This includes activation of microglia 
and astrocytes (Gordon et al., 2002), which can elicit cytokine release, acute 
phase reactants and free radical production. APP production is even thought to 
be promoted by interleukin 1 demonstrating the role that cytokines may have on 
disease progression (Blume and Vitek, 1989). Transcriptional regulation of IEG 
expression by cytokines has been well established (Emch et al., 2001;Konsman 
et al., 2000) and, while this is a possible mechanism by which IEG expression is 
being inhibited, it is unlikely because IEG expression is significantly decreased 
by 6 months in the APP+PS1 mice, a point at which amyloid is accumulating with 
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little inflammatory response (Gordon et al., 2002;Apelt and Schliebs, 2001). In 
addition, most reported cytokine effects on IEG expression have shown that 
increased cytokine production elicits an increase in IEG expression, not a 
decrease (Jenab and Quinones-Jenab, 2002;Simi et al., 2002;Heinrich et al., 
2003). 
Besides the elegant possibilities discussed above, there is perhaps a 
more rudimentary explanation for impaired IEG induction; that the neurons simply 
cannot conduct adequate electrical impulses any longer. One of the plasticity-
related genes with consistently down-regulated mRNA expression in amyloid-
containing APP+PS1 mice tissue was Na+/K+ ATPase αIII (Paper I; Figure 1: 
Paper II; Figures 1, 2 and 3: Paper III; Figure 1).  Na+/K+ ATPase is more than a 
plasticity-related gene in that it consumes nearly 40% of the ATP in brain tissue 
and maintains the membrane potential throughout the parenchyma, emphasizing 
its critical role in every function of the brain. Without Na+/K+ ATPase, neurons 
would not be able to maintain membrane potentials resulting in the loss of their 
ability to conduct electrical impulses and subsequently store information (Watts 
and Mark, 1971). To ascertain whether this enzyme was malfunctioning in the 
APP+PS1 mice, we analyzed the activity of oubain-sensitive ATPase in cerebral 
tissue of memory-deficient APP+PS1 mice compared with non-transgenic 
littermates. We found that there was significantly impaired Na+/K+ ATPase 
activity in the hippocampi of APP+PS1 mice, but not in the cerebella (Paper III; 
Figure 2). These findings suggested that the reduced activity is precipitated by 
the presence of amyloid.  
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Subsequent histological analyses of APP+PS1 cerebral sections showed 
that although Na+/K+ ATPase stained the sections ubiquitously, the area 
immediately surrounding Congo red stained plaques lacked Na+/K+ ATPase 
almost entirely (Paper III; Figures 4 and 5). The absence of Na+/K+ ATPase from 
this circumferential zone around plaques would disrupt the membrane potential 
of any cellular components in that area, which is the exact area where dystrophic 
neurites are normally seen. Triple staining of Na+/K+ ATPase, dystrophic 
neurites and congophilic plaques revealed that the dystrophic neurites were in 
fact within the Na+/K+ ATPase-free zone surrounding the fibrillar plaques (Paper 
III; Figure 5). Soluble Aß was subsequently prepared in accordance with Stein et 
al. (2002) and incubated with purified cerebral Na+/K+ ATPase to assess 
whether or not amyloid could directly inhibit enzyme activity. Interestingly, high 
concentrations of this Aβ preparation did dramatically inhibit activity (Paper III; 
Figure 6), suggesting that in a local area of high amyloid concentration, such as 
the area immediately surrounding an amyloid plaque, Aβ may bind to Na+/K+ 
ATPase leading to its inactivation and subsequent removal from the membrane.  
It has also been reported that specific inhibition of Na+/K+ ATPase leads to 
reduced mRNA expression of the αIII subunit (Huang et al., 1997), providing an 
explanation as to why the mRNA expression is also down-regulated. 
 One of the hallmark pathological features of the APP+PS1 mouse is the 
presence of dystrophic neurites without actual synaptic or neuronal loss (Gordon 
et al., 2002;Jantzen et al. In Preparation). These dystrophic neurites are 
synapses that are presumably no longer functioning properly and appear swollen 
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and disjointed. The exact mechanism by which these neurites form is largely 
unknown, although it has been postulated that amyloid interacts with various 
surface proteins which in turn stimulate signaling cascades and consequently 
lead to the accumulation of hyper-phosphorylated neurofilament and the 
formation of dystrophic neurites (Grace and Busciglio, 2003). Here we have 
presented evidence that in models of amyloid deposition, the AD-like dystrophia 
may occur due to amyloid directly inhibiting Na+/K+ ATPase activity, resulting in 
ionic imbalance and the resultant osmotic swelling (Cooke, 1978). Presumably, 
synapses that have become dystrophic are no longer able to conduct action 
potentials to the post-synapse. Possibly, neurons in an amyloid-induced 
dystrophic state increase expression of several anti-apoptotic genes (Chaudhury 
et al., 2003;Tortosa et al., 1998) leading to the down-regulated expression of 
genes involved in neurotransmitter release. This would suggest that neuronal 
function turns from the collective parenchymal purpose of information transfer to 
the more immediate necessity of survival. Another possibility may be that 
dendritic swelling brought on by osmotic imbalance via Na+/K+ ATPase inhibition 
could actually hamper post-synaptic conduction simply by increasing the area 
(intracellular volume) that the current has to traverse. This may impede the ability 
of gray matter to propagate electrical signals along the entire length of the 
dendritic spine, preventing sufficient depolarization at the axon hillock for 
subsequent synaptic transmissions.   
Based on the results described here, it is feasible that the blockade of 
Na+/K+ ATPase activity by amyloid results in the dysregulation of the neuronal 
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membrane potential which in turn leads to the appearance of swollen, 
dysfunctional neurites. The inability of these neurons then to conduct action 
potentials and elicit specific stimulatory signals like LTP may result in the 
formation of improper synaptic connections, damaged plasticity, and a general 
failure to consolidate information received in the form of discrete patterns of 
electrical frequencies into lasting memories. Late phase LTP, which has been 
linked to long-term memory consolidation (Nadel and Moscovitch, 1998;Abraham 
et al., 2002), is reported to be a critical component of molecular plasticity events, 
namely that late-phase LTP blockade results in inhibition of IEG expression 
(Richardson et al., 1992;Abraham et al., 1993;Barnes et al., 1994). The amyloid-
induced neuritic dystrophia described above may be disrupting the connectivity of 
circuits critical for memory formation, leading to the inability of neurons to 
conduct late-phase LTP. This may prevent the expression of IEGs and the 
subsequent effects on necessary persistent plasticity changes elicited by their 
induction.   
Circuits essential for learned behavior have been well established and 
generally initiate in the hippocampus, with projections to the entorhinal cortex 
and parietal cortex (Izquierdo and Medina, 1997). After repeated training, only 
the parietal cortex is required for recall of this specific task, while the 
hippocampus and entorhinal cortex are no longer involved. It has also been 
established that LTP-induced protein expression is required for these circuitous 
network changes to occur and be maintained (Guzowski et al., 2000;Frankland et 
al., 2001). This suggests that disruption of the ability of these particular circuits to 
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relay electrical signals would result in the inability to form lasting connections 
essential for memory formation, as experienced by Alzheimer’s diseased patients 
and amyloid mouse models.  Additionally, it may not be the sheer volume of 
forebrain amyloid that is driving these memory deficits, but rather where 
specifically the amyloid is depositing, possibly explaining why behavioral deficits 
do not always correlate with IEG expression or amyloid load (Holcomb et al., 
1999). In other words, as amyloid load increases, the chances of a plaque 
depositing in the middle of a long-term memory circuit are significantly increased. 
Therefore, the critical issue in amyloid-associated dementia may not be how 
much amyloid is present, but rather where the amyloid is deposited and what 
neuronal networks are being disrupted.  
Here we have presented evidence that amyloid plaques locally inhibiting 
Na+/K+ ATPase activity in APP+PS1 mice, may result in disruption of electrical 
signaling in brain regions essential for the establishment of lasting forms of 
memory by promoting neuritic dystrophia. This disruption would likely result in 
reduced IEG expression due to the resultant insufficiency of electrical signaling. 
The reduced IEG expression at 6 months in APP+PS1 mice (Paper II; Figure 1) 
is possibly a result of inactivated Na+/K+ ATPase, however sufficient disruption 
of the circuits essential for memory consolidation are yet to be realized as 
amyloid burden is still relatively low. Only when plaque load increases are 
networks adequately impaired to cause detectable memory deficits. These 
findings present several candidates for pharmacological intervention in amyloid-
associated dementia, including several IEGs as well as other plasticity-related 
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genes (e.g. CaMKIIα and AMPA1). The exact mechanisms by which these genes 
are dysregulated and their link to memory formation have yet to be understood. 
However, we have demonstrated a close relationship between amyloid and 
impaired expression of several memory-associated genes, as well as a direct 
inhibition of Na+/K+ ATPase activity by amyloid, suggesting that therapeutic 
intervention targeting the well characterized enzyme may be warranted. 
Maintaining the ionic balance of critical mnemonic circuits through the 
administration of Na+/K+ ATPase agonists like phenytoin, may prove highly 
therapeutic to AD sufferers, possibly delaying the emergence of cognitive 
symptoms for several years and reducing medical and long-term care costs by 
billions of dollars.   
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TABLE 1.  Genes that are selectively and significantly down-regulated in 
the amyloid-containing hippocampi of APP+PS1 mice (qRT-PCR data). 
 
Category Gene Name NCBI Genbank Accession # 
qRT-PCR Data 
Percentage of 
nontransgenic 
mean ± SEM 
Arc (Arg3.1) NM_018790 48+10 
Zif268 (Egr-1) M20157 45+ 8 
Nur77 (Nurr1) J04113 60+ 8 
Homer1a (Vesl-1) AF093257 60+ 7 
Narp (Nptx2) AF049124 62+ 8 
Immediate-Early 
Genes 
β-A Activin D83213 69+ 7 
CaMKIIα NM_009792 65+ 6 
AMPA1(GluR 1) NM_008165 70+10 
NR2B NM_008171 82+ 5 
Na+/K+ ATPase BC020177 57+ 4 
Other Plasticity-
Related Genes 
PSD-95 D50621 82+ 5 
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APPENDIX A: QUANTITATIVE REAL TIME PCR (QRT-PCR) PROTOCOL 
 
Primer Design. 
1. Using the gene of interest (GOI), find the accession number that 
corresponds to the proper species with cDNA or mRNA at the end of the 
name, and copy and paste the sequence into a word processor. 
2. Delete about 50% of the 3’ end of this sequence, as eukaryotic RNA 
degrades from that end. 
3. Using the internet based primer design program called Primer3 
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi), paste 
the shortened sequence into the proper field. 
4. Set the specification of the amplicon size to be within 75-200bps, optimally 
@ 100bp. Also use the rodent mispriming library available with the 
program. 
5.  Specify the Tm (annealing temperature) to range be between 60˚C and 
65˚C. 
6. Also set the GC content between 50 and 60%. The primers should have 
~55% GC content and their Tm should be within 1-2˚C of each other. 
7. Select the number to return field and type in 20. This will return 20 
possible pairs rather than the standard 5 pairs the program uses for 
default. 
8. The program returns possible primer pairs in different regions of the 
sequence, with the best option listed first. 
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9. Select a primer set  in which both have similar properties, particularly the 
same GC content as this determines Tm and check their self-hybridization 
properties on the Operon website in their “Oligo Toolkit”.  
10. Any pair with more than 4 nucleotides having primer-dimer potential are 
not used. 
11. The Operon website is also where the Tm is derived that should be use in 
the actual PCR reaction.  
12. Then search Genbank for sequence homology of the F primer. If a match 
of 15 or more nucleotides are found in the same species, check the 
reverse complimentary sequence of the R primer in a similar manner. If 
matches of 15 or greater are found for both, do not use the primers and 
select a new set from the Primer 3 output.  
13. After finding no evidence of other potential targets, primers are ordered 
from IDT. 
 
RNA Extraction. 
1. Frozen tissue dissections are homogenized using a tissue-mizer 
instrument for 30 seconds in 700ul of RLT buffer plus β-mercaptoethanol 
(see Qiagen RNeasy protocol). The rotor-stator is rinsed with clean water 
and 70% ethanol between samples and dried with a Kim-Wipe. 
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2. Qiagen RNeasy mini-spin columns are used to purify RNA according to 
Qiagen’s protocol. Additionally, samples were treated with RNase-free 
DNase from Qiagen.  
3. 20mg of tissue/column is the ratio used, yielding approximately 16ug total 
RNA/20mg of brain tissue. 
4. RNA was eluted in water and total RNA concentration was determined by 
Ribogreen Assay (Molecular Probes) using a standard curve (See 
Molecular Probes Protocol). 
5. The concentration is adjusted to 50ng/ul and RNA quality is checked by a 
1% agarose gel with ethidium bromide. 
 
Reverse Transcription. 
1. The reverse transcription (rev txn) is performed using 8 mass quantities of 
total RNA diluted down from a 50ng/ul standard intra-assay sample pool. 
This should cover 3 logs (50, 20, 10, 5, 2, 1, 0.5, 0.2ng/ul).  For single 
samples, make a 1:10 dilution of each with water to yield 5ng/ul. 
2. Plan ahead about how many genes you want to analyze and the number 
of samples you have. 24 samples allows for a single PCR plate to be used 
per gene with triplicates of each plus the standards. More than 24 samples 
requires that two plates be used for each gene and therefore duplicate 
standards on each of these plates must be  
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accounted for (quadruplicates in total) to control for plate-to-plate 
variation.   
3. Additionally, pipetting is critical for real time PCR, so using 8-strip PCR 
tubes, mini-master mixes are made for each sample and standard to draw 
replicates (triplicates, quadruplicates, etc.) from. Therefore, a slight excess 
is required in each tube, making enough for 3.5 replicates or 4.5 
replicates. This adds to the total number of cDNA needed from the 
beginning. 
4. Therefore, each gene will require at least 7ul (for 3.5 triplicates) of cDNA 
per sample and each reverse transcription reaction is 20ul, so nearly 3 
genes can be analyzed per reverse transcription reaction.  
e.g. 9 GOIs * 7ul = 63ul. Therefore 3.5 reverse transcription reactions 
(70ul) would be needed for each sample and standard to allow for 
complete analysis of all 9 GOIs.  
5. The following equation will yield the total number of reverse transcription 
reactions needed: 
# of samples (24) + # of standards (8) * number of rev txn reactions (3.5)  
=  total # of rev txn reactions (112 Æ round to 118 to have enough 
excess). 
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6. Make a master mix for the total # of rev txn reactions using the following 
components (volumes are based on a single rev txn reaction rather than 
the total needed for the 118 reactions mentioned above) 
a. 0.5ul of 500ng/ul Oligo d(T) 15-21 
b. 0.5ul of 500ng/ul Random Hexamers 
c. 4ul of 5x 1st Strand Buffer 
d. 4ul of 25mM MgCl 
e. 2ul of DTT 
f. 1ul of dNTPs 
g. 6ul of 5M Betaine (provides thermostabilization to RT enzyme and 
enhancing denaturation) 
h. 0.87ul RNAse free water (vortex here prior to addition of enzyme) 
i. 0.13 200U/ul MMLV reverse transcriptase 
7. Mix by pipetting, and aliquot required volume minus RNA (19ul * number 
of need RT reactions) into  a 96-well hard shell PCR plate 
8. Transfer 1ul * the number of needed RT reactions of 5ng/ul sample RNA 
or varied concentration standard RNA  into corresponding tubes 
9. Mix by pipetting, cover with film (MJ Research Microseal A) and place into 
the thermal cycler. 
10. Create a program for 10 minutes at 25°C, 30 minutes at 42°C, 30 minutes 
at 60°C and 5 minutes at 95°C to kill the enzyme and stop the reaction. 
11. After this is finished, spin gently and use as cDNA. 
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Primer Optimization. 
1. This step is important, particularly for SYBR green reactions that lack the 
specificity of Taqman probes and require a melt curve analysis. 
2. The qRT-PCR reactions can be run at 50ul or 25ul/well, but with 25ul, 
extra care must be given to sealing the plate because evaporation can 
occur on the edge wells. 
3. Primers for GOI are diluted to 100uM stocks in water and then further 
diluted 1:20 to 5uM in water. 
4. The cDNA from the rev txn reactions is not cleaned up or purified in any 
way and added straight to the PCR reactions. Any species specific cDNA 
pool at 50ng/ul can be used for the primer opt to spare that which was just 
made. 
5. Using the primer design parameters mentioned above, the final in-well 
concentration of F and R primers is usually 300nM each. To save 
reagents, do an initial screening at these concentrations and look at the 
melt curve analysis. Therefore the reaction mix for a single PCR reaction 
of a single sample is as follows (multiply by the # of PCR reactions 
needed, usually 3.5 per samples): 
a. 12.5ul of 2x SYBR green master mix  
b. 7.5ul water 
c. 1.5ul F primer 
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d. 1.5ul R primer 
e. 2ul cDNA 
6. Aliquot enough mix for 3.5 reactions (replicates) into 8 strip PCR tubes 
and then mix 10 times with cDNA . Aliquot 25ul from these 8-strip PCR 
tubes to corresponding wells of a 96-well hard skirted PCR plate. 
a. Be very careful when making the replicates during aliquoting that 
excess reaction does not get into the wells from one replicate to the 
other (the viscosity of the mix due to the presence of Tris/DMSO 
may cause the liquid to cling to the outside of the tip). Be sure to 
use filter tips for everything and mix the master mix very well before 
aliquoting into the plate. 
b. The plates (MJ Research) used are specially designed as well as 
the film (MJ Research Microseal B) that covers them to be optically 
clear. 
7. Plates are then spun at a low speed and then can be stored at 4˚C for 24 
hours. 
8. The PCR is as follows: 
a. 1 cycle of 95˚C for 5 minutes (this activates the hot start Taq) 
b. 40 cycles of: 
i. 95˚C for 15 seconds 
ii. Suggested annealing temperature from Operon (58-65˚C) for 
1 minute 
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c. Then the melt curve program runs which starts at 55˚C and 
increases 0.5˚C every 10 seconds until 100˚C. It measures 
fluorescence at each interval and a derivative equation is used to 
show a peak where the fluorescence drops off dramatically. This 
uses the principle of SYBR as a double strand specific intercalating 
dye. 
9. There should be little or no reactivity in the NTCs, precise replicates, and 
the melt curve analysis should show a single peak. If the melt curve shows 
multiple peaks, new primers must be optimized and ordered. 
 
Quantitative Real Time-PCR of Samples. 
1. Once suitable primer pairs are found, use the same principles discussed 
above in the Primer Optimization section to analyze expression of the 
cDNA from the samples of interest that were reverse transcribed also 
described above in the Reverse Transcription section.  
 
Quantification and Statistical Analyses. 
1. The slope of the line generated from plotting the threshold cycle (y-axis) 
against the log ng RNA in the standard curve indicates the efficiency of 
the reaction. In order to compare expression of 2 genes or to use a non-
changing internal control (e.g. 18S rRNA or 28S rRNA) for mathematical  
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manipulations and determination of significance, the slopes must be within ± 
0.1 of each other and have a R2-value of no less than 0.95. 
a.  A reaction that is 100% efficient will have a slope of -3.3, however 
this is uncommon when using reverse transcriptase which is a very 
inefficient reaction. Normally the slopes are less efficient, around -
4.0 (~75%). 
2. Using the equation of the best fit line, threshold cycles from samples can 
be used to calculate how many log nanograms of RNA from the GOI are 
present. The anti-log of this value is then taken to determine actual 
nanograms of RNA. 
3. The GOI value is then divided by the internal standard control (18S or 
28S) and this gives the fold change in expression.  
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Reagents. 
1. Protein (Tissue) Resuspension Buffer (1L) 
a. 85mM NaCl (4.97g) 
b. 20mM KCl (1.49g) 
c. 4mM MgCl (0.813g) 
d. 0.2mM EGTA (0.076g) 
e. 30mM Histidine (4.66g) 
2. ATPase Buffer (1L) 
a. 140mM NaCl (8.18g) 
b. 20mM KCl (1.49g) 
c. 3mM MgCl (0.61g) 
d. 30mM Histidine (4.66g) 
e. 3mM ATP (1.65g) 
f. +/- 100uM Oubain 
g. Filter Sterilize for longer shelf life 
h. May change color, remake 
3. Acid Molybdate Solution (100mL) 
a. 0.5g Ammonium Molybdate in 0.5M H2SO4 
b. If precipitate forms or color changes, remake 
4. Saponin 
a. Make 2mg/ml stock in water 
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5. Coloring Agent (Fiske-Subbarow Reducer) 
a. 5g in 31.5mL 
b. Store in amber bottle (Foil tube) @ RT 
c. Good for 1 month 
6. Phosphate Standard Solution 
a. 4mM phosphoric acid 
 
Procedure. 
1. Homogenize 20-30mg brain tissue in 1mL of cold protein resuspension 
buffer by rotor-stator for 30-45secs. Place on ice. 
2. Add 10uL of 2mg/ml saponin to 1mL of homogenate (final conc. = 
20ug/uL), incubate @ 37C for 15min, and place on ice. 
3. Run Bradford Assay and adjust protein concentrations accordingly with 
protein resuspension buffer (minimum of 10mg/mL tissue weight or ~ 
1mg/mL protein). 
4. In 96-well V-bottom plate, create standard curve with Phosphate Standard 
Solution, making 7 2-fold dilutions beginning from 4mM (triplicates -- final 
volume should be the same as protein sample wells). 
5. Add 60uL of ATPase Buffer +/- oubain to wells in the same V-bottom plate 
in step 4 for protein samples to be analyzed (triplicates for (-) oubain and 
(+) oubain, therefore, you need six wells per sample). 
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6. Add 5-10ug protein (50-100ug tissue weight) to wells, mix and incubate @ 
37C for 30min. 
7. Add 120uL Acid Molybdate Solution to all wells, mix, then add 10uL of 
Fiske-Subbarow Reducer, mix and incubate for 10min @ RT. 
8. Centrifuge plate so that any precipitate is pelleted, and transfer 100uL to a 
flat-bottom optically clear plate (not polypropylene). 
9. Read spectrophotometrically at 660nm. 
10. Use the equation of the line from the standard curve to convert OD to 
concentration of phosphate (mM). 
11. Subtract the +oubain values from the –oubain values, then use this 
difference to calculate how much phosphate was generated specifically by 
Na+/K+ ATPase.  
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Mouse Neuroblastoma 2A (N2A) Maintenance. 
1. Adherent N2A cells frozen in 95% complete media (Earl’s minimum 
essentials medium (EMEM) + 10% heat inactivated fetal bovine serum 
(FBS) + 1% penicillin/streptomycin solution (PS) with 5% DMSO are 
rapidly thawed upon removal from nitrogen. 
2. Cells are immediately placed into 20ml of warm complete medium in a 
vented T-75 flask and allowed to incubate at 37°C until 90% confluent. 
3. Cells should be passaged every 3-4 days by treatment with 0.25% (w/v) 
Trypsin- 0.53 mM EDTA solution for 5 minutes and followed by scraping. 
All traces of serum that contains trypsin inhibitor should be removed with a 
PBS wash prior to adding trypsin-EDTA. 
4. Cells in trypsin are then passaged to new flasks with 20ml of fresh 
complete medium. 
 
Differentiation of N2A Cells. 
1. N2A cells can be treated with dibutyryl-cAMP to facilitate differentiation 
from their oncogenic state to a neuronal state. 
APPENDIX C: (CONTINUED) 
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2. N2A cells are subcultured and added to 6 well plates at 50-60% 
confluency (equivalent to 1 T-75 flask passaged to 3 6 well plates), and 
are permitted to reattach overnight in complete medium. 
3. Complete medium is then removed and cells are rinsed with PBS. 
4. Dibutyryl cAMP (db-cAMP) is added at a concentration of 1mM to serum-
free EMEM + PS, which is then applied to the cells in the 6 well plates.  
5. These cells are then actively differentiating into neurons which is visible 
under the microscope by the presence of extended neurites. This process 
is allowed to continue for 48-72 hours. 
6. These cells can then be treated with nerve growth factor (mouse maxillary 
NGF-2S) by directly applying the NGF solution to a final in-well 
concentration of 100nM.  
7. After 1 hour, remove media from wells and rinse with PBS. 
8. Add 350ul of RLT buffer with β-mercaptoethanol to the cells in each well, 
scrape, and aspirate liquid into a Qiashredder tube. 
9. Spin down at max speed for 3 minutes, remove Qiashredder from 
collection tube and begin RNA isolation as described by the RNeasy 
Qiagen protocol for animal cells. NGF elicits the induction of several 
immediate early genes in differentiated Neuro2A cells as measured by 
qRT-PCR (Figure 1).  
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Preparation of 5mM Aβ Peptide Stock Solutions. 
1. Recombinant amyloid peptide (1mg) purchased from rPeptide (Cat # A-
1002-2) is used to prepare monomeric, oligmeric and fibrillar forms of Aβ. 
2. Using a Gastight Hamilton syringe, draw 221.7ul of cold 1,1,1,3,3,3 
Hexafluoroisopropanol (HFIP) and puncture the rubber cap of the Aβ vial 
to resuspend the powder.  
3. Allow the solution to stand at room temperature for 30 minutes and 
sonicate for 5 additional minutes. 
4. Aliquot the suspension into microcentrifuge tubes (VWR # 20170-293), in 
a 10ul (45ug) amount. 
5. Allow the HFIP to evaporate overnight in a fume hood leaving only a thin 
film of Aβ present at the bottom of the tube. 
6. The next day, speedvac the tubes for 1 hour without heat to remove all 
traces of liquid. These can be stored at -20°C on desiccant for several 
months. 
7. To use the Aβ right away, resuspend the 45ug film in 2ul of freshly opened 
dry DMSO (Sigma # D2650) to yield a 5mM stock Aβ solution. Vortex 
thoroughly and sonicate for 5 minutes. 
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Preparation of Monomeric Aβ. 
1. Dilute the 5mM Aβ DMSO stock with 98ul of water to yield a 100uM 
preparation of monomeric Aβ. Then vortex and use.  
 
Preparation of Oligomeric Aβ. 
1. Dilute the 5mM Aβ DMSO stock with 98ul of ice cold phenol-free (phenol-
red-free) Ham’s F-12 culture medium to yield a 100uM preparation of 
oligomeric Aβ. 
2. Vortex and incubate overnight at 4°C. For optimal performance, this 
should be used on the following day. 
 
Preparation of Fibrillar Aβ. 
1. Dilute the 5mM Aβ DMSO stock with 98ul of 10mM HCl to yield a 100uM 
preparation of fibrillar Aβ. 
2. Vortex and incubate overnight at 37°C.  
3. The following day, neutralize acid with equimolar amount of NaOH. For 
optimal performance, this should be used on the following day. 
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APPENDIX C: (CONTINUED) 
FIGURE 1. Induced expression of IEGs in differentiated N2A cells  by nerve 
growth factor measured by qRT-PCR. 
   This figure shows NGF treated (gray bars) and non-treated (black bars) 
db-cAMP differentiated Neuro2A expression (gray bars) as a percentage of 
the average of undifferentiated Neuro2A cells (set as 100%) for the 
immediate early genes (IEGs) Zif268, Arc, and Nur77. This figure 
demonstrates that in Neuro2A cells differentiated for 72 hours with db-cAMP, 
NGF causes a robust increase in IEG expression. Additionally, Na+/K 
ATPase αIII expression, which is selectively over-expressed in neurons 
compared to non-differentiated neuro2A cells, has increased expression in 
the db-cAMP treated Neuro2A cells, quantitatively demonstrating that 
differentiation of Neuro2A cells into neurons was being facilitated by the db-
cAMP treatment.   The values represented in this figure are the mean + SEM. 
“*” indicates significant differences between db-cAMP differentiated Neuro2A 
expression and undifferentiated Neuro2A (p < 0.05) when measured by one-
way ANOVA. "†" above the bracket indicates differences (P < 0.05) in 
expression between NGF-treated db-cAMP differentiated Neuro2A cells and 
non-treated db-cAMP differentiated Neuro2A cells. 
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